Obatoclax Mesylate (GX15-070)

Catalog No.S1057

Molecular Weight(MW): 413.49

Obatoclax Mesylate (GX15-070) is an antagonist of Bcl-2 with K_i of 0.22 μM in a cell-free assay, can assist in overcoming MCL-1 mediated resistance to apoptosis. Phase 3.

Cited by 26 Publications

Nat Chem Biol, 2015, 10.1038/nchembio.1986

PubMed: 26656090

Cancer Res, 2012, 72(12):3069-79

PubMed: 22525702

Cancer Res, 2011, 71(13):4494-505

PubMed: 21555370

ACS Appl Mater Interfaces, 2016, 8(21):13218-31

PubMed: 27160664

Oncogene, 2012, 32(37):4331-42

PubMed: 23085751

Cancer Lett, 2015, 10.1016/j.canlet.2015.05.008

PubMed: 25979228

Cancer Lett, 2014, 348(1-2):20-8

PubMed: 24534203

Cancer Lett, 2012, 339(2):288-97

PubMed: 23200668

Cell Death Dis, 2013, 4:e742

PubMed: 23887633

Cell Death Dis, 2012, 3:e351

PubMed: 22825469

Cell Death Dis, 2012, 3:e299

PubMed: 22513873

Mol Oncol, 2015, 9(2):409-21

PubMed:
Oral Oncol, 2014, 50(2):120-7

PubMed: 24216166

Antimicrob Agents Chemother, 2014, 58(7):3689-96

PubMed: 24752266

Biochem Pharmacol, 2014, 92(1):55-61

PubMed: 25107702

J Biol Chem, 2014, 289(38):26481-91

PubMed: 25096574

Exp Cell Res, 2014, 322(1):217-25

PubMed: 24355809

Open Biol, 2015, 5(3)

PubMed: 25761368

Life Sci, 2014, 10.1016/j.lfs.2014.07.006

PubMed: 25066930

J Cell Biochem, 2014, 115(9):1624-35

PubMed: 24788582

PLoS One, 2014, 9(9):e106571

PubMed: 25192188

PLoS One, 2013, 8(2):e55982

PubMed: 23418490

Anticancer Drugs, 2015, 26(3):331-42

PubMed: 25521557

Arch Pharm Chem Life Sci, 2015, 348: 1-11

PubMed: 25641608
Erasmus University Rotterdam, 2014, 978-94-6259-077-9

PubMed: http://repub.eur.nl/pub/50827/

Helsinki Metropolia University, 2013, Jens Desloovere

PubMed:

9 Customer Reviews

In vivo antitumor efﬁcacies of AZD2281 and GX15-070 alone or in combination in a BxPC-3 xenograft model. Tumor specimens were fixed in 10% formalin, embedded in paraffin, and cut into 4 lm-thick slides for H&E, PCNA, and CD34 staining.

Cancer Lett 2014 348, 20-8. Obatoclax Mesylate (GX15-070) purchased from Selleck.

Gx15-070 induces autophagy and necroptosis in TET cells. Time-course electron microscopic morphology of T1682 cells treated with Gx15-070 at the indicated concentrations. After 1-h treatment, lamellar bodies (yellow arrow) consistent with early signs of autophagy and mitochondrial structural changes with loss of cristae (orange arrow) were evident. After 6-h treatment, early signs of necroptosis with intact nuclear envelope (top panel), and mitochondrial swelling with loss of mitochondrial matrix and cytoplasm vacuolization were observed (bottom panel). After 48-h treatment, late stages of necroptotic cell death (yellow arrow) and advanced stages of autophagy (orange arrow) were evident. The bottom panel depicts advanced stage of autophagic cell death with cytoplasmic vacuolization and lamellar bound structures consistent with autophagosomes.

Cell Death Dis 2012 19, 3:e351. Obatoclax Mesylate (GX15-070) purchased from Selleck.
ffect of Gx15-070 of mTOR pathway and on AMPKα. Effect of 6h Gx15-070 treatment on T1682 cells compared with untreated cells and cells starved for 6 h. The treatment induced a progressive reduction of p-AKT (Ser473 and Thr308) and p-RPS6 with the exception of 500 nM concentration. Progressive increase of LC3B-II and AMPKα phosphorylation was observed in Gx15-070 concentration-dependent manner.

Cell Death Dis 2012 19, 3:e351. Obatoclax Mesylate (GX15-070) purchased from Selleck.

Upregulation of A1 is crucial for resistance to ABT-737. The role of different anti-apoptotic Bcl-2 factors in determining resistance to ABT-737 was investigated, comparing the pro-apoptotic effect of ABT-737, antimycin A and obatoclax on activated (filled circles) and non-activated (open circles) BM3.3 CD8 T cells. T-cell activation induced resistance to ABT-737 and to antimycin A, but not to obatoclax, demonstrating a crucial role of A1 in this phenomenon. Percentage of cells treated with DMSO-containing vehicle is given. Half maximal inhibitory concentration (IC50) and 95% confidence interval (95% CI) are reported in the table.

Cell Death Dis 2012 3, e299. Obatoclax Mesylate (GX15-070) purchased from Selleck.
HUH6 cells (C-H) were incubated with and without 10 ng/ml TNF-α and obatoclax at 0.1, 0.3 uM. Fewer mitochondria with an intact membrane potential were observed in JC-1 staining when obatoclax and TNF-α were added to the culture. Reddish points indicate the aggregation of JC-1 in intact mitochondria, and missing of reddish points indicate the start of apoptosis.

Exp Cell Res 2014 322, 217-25. Obatoclax Mesylate (GX15-070) purchased from Selleck.

Cell proliferation assays were carried out in SET-2 cells treated with increasing concentrations of NVP-BSK805 (empty triangles/solid line), obatoclax (filled squares/dotted line) or NVP-BSK805 in combination with a fixed obatoclax concentration of 700 nM (filled triangles/stippled line) for 72 hours.

BMC Cancer 2011 11, 24. Obatoclax Mesylate (GX15-070) purchased from Selleck.
MEF cells were treated for 24 hours with the Bcl-2 antagonists Obatoclax Mesylate at the indicated doses.Acute survival was monitored by replacing the drug-containing media with normal media and incubating the cells until visible colonies formed.Clonogenic survival is expressed relative to the numbers of colonies formed following 24 hours incubation in normal media(lacking drugs).

Dr. Christine Hawkins of La Trobe University. Obatoclax Mesylate (GX15-070) purchased from Selleck.

MDB-MA-231 cells were exposed to 30 μM cisplatin in the absence or in thepresence of 1 μM Obatoclax Mesylate .The cell were stained with Hoechst 33342,MitoTracker Red and Yo-pro-1.

Dr. Zhang of Tianjin Medical University. Obatoclax Mesylate (GX15-070) purchased from Selleck.
Obataclax triggers cell death similarly in parental and ABT-737-resistant cells. Parental and ABT-R cells were treated with obataclax (Nalm-6 and Nalm-6 ABT-R: 10 uM; Reh and Reh ABT-R: 5 uM) for 18 h. (A) Cell viability was determined by trypan blue exclusion assay. (B) Mcl-1, NOXA, Bim, and b-actin as a loading control were analyzed by immunoblot.

Obatoclax Mesylate (GX15-070) purchased from Selleck.

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Biological Activity

Description

Obatoclax Mesylate (GX15-070) is an antagonist of Bcl-2 with K_i of 0.22 μM in a cell-free assay, can assist in overcoming MCL-1 mediated resistance to apoptosis. Phase 3.

Features

Potential 1st-in-class small molecule antagonist of Bcl-2 designed to inhibit all relevant Bcl-2 family members, including Mcl-1.

Targets

Bcl-2 ^[1]
(Cell-free assay)

0.22 μM(Ki)

In vitro

Obatoclax completely inhibits Bak recovery of Mcl-1 at 5 μM in SK-Mel5 cells and overcomes resistance to ABT-373-induced apoptosis conferred by Mcl-1 in KB/Bcl-2 cells. ^[1] Obatoclax is a BH3 mimetic which binds to a broad spectrum of Bcl-2 family members, including Bcl-2, Bcl-xL, and Mcl-1. Obatoclax uniquely displaces BH3 domains by activation of the pocket of Mcl-1 followed by a triggering of apoptosis mediated by oligomerization of Bak and release of cytochrome c. Obatoclax is sensitive to Bcl-xL in cell lines lacking it or showing low expression. It shows low cytotoxicity to Mcl-1, Bcl-2, and Bcl-xL in all the strongly-expressed cell lines. Obatoclax inhibits multiple myeloma (MM) cell lines (KMS12PE, KMS18, MY5, etc.) with IC50 values ranging from 52 to 1100 nM and the inhibition is umimpaired even in the presence of IL-6 or IGF-1, which are resistance to cytotoxic agents, at a concentration of 150 nM. Obatoclax enhances the antimyeloma activity induced by melphalan, dexamethasone, or bortezomib. ^[2] Obatoclax potentiates TRAIL (tumor necrosis factor-related apoptosis-inducing ligand)-mediated apoptosis by unsequestering Bak and Bim from Bcl-2/Bcl-xL or Mcl-1 proteins in PANC-1 and BxPC-3 cells. ^[3]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
KARPAS-45	MnrvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlvmTWM2OD1yLkCwNFA{OTdizszN	NVLpd3NkW0GQR1XS
SK-MEL-30	NH\2bZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVPJR\|UxRTBwMECwN\|U2KM7:TR?=	NVu0XG9TW0GQR1XS
NALM-6	NInsPYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2XuPGlEPTB;MD6wNFA{PTZizszN	NFHFSXBUSU6JRWK=
KYSE-450	NEG5b4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXi2NGdbUUN3ME2wMlAxODR4OTFOwG0>	NVLtZVl5W0GQR1XS
BHY	NIfFRZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{nacmlEPTB;MD6wNFA3ODFizszN	NVO5dXhiW0GQR1XS
GR-ST	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{XFdGlEPTB;MD6wNFA3PDhizszN	NITYeFFUSU6JRWK=
786-0	M4\lR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX;JR\|UxRTBwMECwO\|c3KM7:TR?=	NWXae5ZwW0GQR1XS
C-33-A	MknHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXjJR\|UxRTBwMECwPFQ5KM7:TR?=	NFW1ZXZUSU6JRWK=
BHT-101	MnzBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4HrfWlEPTB;MD6wNFExPiEQvF2=	MXLTRW5ITVJ?
EB2	M1LEdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV6xS2lxUUN3ME2wMlAxOTF6IN88US=>	M3;OU3NCVkeHUh?=
G-361	MorES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGLzeIJKSzVyPUCuNFAyOjRizszN	MXnTRW5ITVJ?
KE-37	NGr6ZYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml\hTWM2OD1yLkCwNVI5KM7:TR?=	M4DmZXNCVkeHUh?=
MHH-PREB-1	MlTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4PlWGlEPTB;MD6wNFE1KM7:TR?=	MlrBV2FPT0WU
MCF7	NXXKToVMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWDCeVFuUUN3ME2wMlAxOTV7IN88US=>	NVLCOnRGW0GQR1XS
LOUCY	NYmwSVZET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXXJR\|UxRTBwMECxO\|Uh\|ryP	NXLaNHliW0GQR1XS
EW-7	M3\jOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoTUTWM2OD1yLkCwNVc2KM7:TR?=	NXTJS3NZW0GQR1XS
KYSE-510	NGPOUZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWfJR\|UxRTBwMECyN\|Mh\|ryP	NVjSS2Q5W0GQR1XS
SK-MEL-3	M4XYeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2fPOmlEPTB;MD6wNFI3PCEQvF2=	MX;TRW5ITVJ?
HAL-01	NELKbGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1f5WWlEPTB;MD6wNFI6PyEQvF2=	NECwXI5USU6JRWK=
HCC2998	MornS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUjJR\|UxRTBwMECzN\|Uh\|ryP	NFe3SGZUSU6JRWK=
A375	M{fSTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFO3cZBKSzVyPUCuNFA{PSEQvF2=	M4HxSHNCVkeHUh?=
MZ7-mel	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mo[wTWM2OD1yLkCwN\|k6KM7:TR?=	NXXUUmlDW0GQR1XS
SH-4	NHvicYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWDJR\|UxRTBwMEC0NVch\|ryP	M3fodXNCVkeHUh?=
HT-144	NYLtSml6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MU\JR\|UxRTBwMEC0N{DPxE1?	MnGxV2FPT0WU
KYSE-140	MorzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUPJR\|UxRTBwMEC0N\|Uh\|ryP	MlPmV2FPT0WU
PSN1	NY\zNZdXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGHvN3ZKSzVyPUCuNFA1PjdizszN	NGnKcVJUSU6JRWK=
COLO-679	Mkn2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1TxSmlEPTB;MD6wNFQ6QCEQvF2=	MnqzV2FPT0WU
SW620	MkPoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUfLe4wxUUN3ME2wMlAxPTFzIN88US=>	NHPZRXRUSU6JRWK=
HGC-27	M3\0TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NW\JOWlJUUN3ME2wMlAxPTJ2IN88US=>	NF3nXmVUSU6JRWK=
IGROV-1	NXPDXpNuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGKyV4ZKSzVyPUCuNFA3KM7:TR?=	NFLlRZFUSU6JRWK=
IGR-1	NWS4e25QT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4e2cWlEPTB;MD6wNFYxOSEQvF2=	NEfuc\|lUSU6JRWK=
EW-1	MnLoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{nUSGlEPTB;MD6wNFY2OSEQvF2=	MUXTRW5ITVJ?
769-P	M4TrdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mln6TWM2OD1yLkCwOlc5KM7:TR?=	MoTkV2FPT0WU
HN	MoHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3;hWWlEPTB;MD6wNFY4QSEQvF2=	NVXOflg6W0GQR1XS
SIG-M5	MmPrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2TGO2lEPTB;MD6wNFcyKM7:TR?=	Mo\CV2FPT0WU
IST-MEL1	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{XnXWlEPTB;MD6wNFgyQCEQvF2=	Mk\JV2FPT0WU
ST486	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXO1W3NRUUN3ME2wMlAxQDJ3IN88US=>	MWHTRW5ITVJ?
ES7	Mn\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2q4UGlEPTB;MD6wNFg1PiEQvF2=	MVzTRW5ITVJ?
GAK	MlL0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlexTWM2OD1yLkCwPFQ5KM7:TR?=	M1;CPHNCVkeHUh?=
BB30-HNC	M1P3SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXzJR\|UxRTBwMEC4OVgh\|ryP	MlTSV2FPT0WU
IPC-298	M2\1T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGrCT25KSzVyPUCuNFA6OjdizszN	NFy0[lZUSU6JRWK=
NKM-1	M3HQXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV\JR\|UxRTBwMEC5O\|Ih\|ryP	M2S2W3NCVkeHUh?=
RKO	NYDMW\|l[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIXGOZJKSzVyPUCuNFExPDRizszN	MUXTRW5ITVJ?
ACN	MomzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnTaTWM2OD1yLkCxNVMyKM7:TR?=	M1vTT3NCVkeHUh?=
SW1417	MojNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3vsSGlEPTB;MD6wNVIzPSEQvF2=	NV\sbGlCW0GQR1XS
SR	NFzNb4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnPFTWM2OD1yLkCxNlM2KM7:TR?=	MoLJV2FPT0WU
SNG-M	M2rtbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYrJR\|UxRTBwMEGzNVch\|ryP	MkL2V2FPT0WU
CAL-12T	M3;FfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH\2[INKSzVyPUCuNFE{PDZizszN	M12xO3NCVkeHUh?=
HSC-3	NGHQWYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2LVNGlEPTB;MD6wNVM2PSEQvF2=	NHfRdYFUSU6JRWK=
DOHH-2	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlKyTWM2OD1yLkCxOFEzKM7:TR?=	M32wXHNCVkeHUh?=
NB69	M37kW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MljpTWM2OD1yLkCxOVY2KM7:TR?=	M{LDSXNCVkeHUh?=
LC-2-ad	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEmyO25KSzVyPUCuNFE2QDFizszN	MlnKV2FPT0WU
RVH-421	NUP4bmxxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1vPTmlEPTB;MD6wNVY4PCEQvF2=	M2WyXHNCVkeHUh?=
TGW	MlToS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWPJR\|UxRTBwMEG3N\|kh\|ryP	NFTsTVRUSU6JRWK=
HCC1569	NIO1W5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1XMT2lEPTB;MD6wNVc6PyEQvF2=	MYfTRW5ITVJ?
CAL-85-1	M3LQV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGTTS4JKSzVyPUCuNFE5OzJizszN	M3TYXHNCVkeHUh?=
RPMI-8402	NW\kRmN[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUDJR\|UxRTBwMEG4OVgh\|ryP	M2HlZnNCVkeHUh?=
THP-1	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHn6SWtKSzVyPUCuNFE6QThizszN	NFK3[GtUSU6JRWK=
ONS-76	NWrDUmFxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYrJR\|UxRTBwMEKwN\|Yh\|ryP	NI\NUG1USU6JRWK=
A2780	NXLDd45FT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MW\JR\|UxRTBwMEKwO\|kh\|ryP	Mm\QV2FPT0WU
RPMI-2650	M1S1eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV\pNYlTUUN3ME2wMlAzOjl4IN88US=>	NFjCO\|JUSU6JRWK=
MEL-HO	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUnFXW1nUUN3ME2wMlAzOzR6IN88US=>	NULFdZZGW0GQR1XS
MC-CAR	NVLjOm85T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1[z[2lEPTB;MD6wNlM2PiEQvF2=	NILpUW9USU6JRWK=
HSC-2	M3rXN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVHJR\|UxRTBwMEK0OlYh\|ryP	MnjhV2FPT0WU
MEL-JUSO	Mn32S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3v2RmlEPTB;MD6wNlQ4OyEQvF2=	MonXV2FPT0WU
CAL-62	M4O3PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1LuTGlEPTB;MD6wNlYxOiEQvF2=	MnfuV2FPT0WU
DMS-273	MoewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWfGW\|h2UUN3ME2wMlAzQDR5IN88US=>	MlPGV2FPT0WU
S-117	NUGyVFhDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M12wUWlEPTB;MD6wNlkxPiEQvF2=	M3;D[3NCVkeHUh?=
SUP-T1	NHfWcXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVS4cHBsUUN3ME2wMlAzQTR7IN88US=>	MlLzV2FPT0WU
MZ2-MEL	M{jCRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYrS[nFrUUN3ME2wMlAzQTV7IN88US=>	M{TMUHNCVkeHUh?=
KYSE-270	NFTsU4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF:zSI1KSzVyPUCuNFI6PzZizszN	NUT4R2NpW0GQR1XS
CMK	MmHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlrnTWM2OD1yLkCzNFI{KM7:TR?=	MkTNV2FPT0WU
8505C	NV;HdmdQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnvUTWM2OD1yLkCzNFQh\|ryP	NFHQXoNUSU6JRWK=
NUGC-3	M1zFcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV\JR\|UxRTBwMEOwOFgh\|ryP	NYewPGFmW0GQR1XS
A101D	M1fiTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXXDO\|B4UUN3ME2wMlA{ODV3IN88US=>	MYLTRW5ITVJ?
G-401	M2XP[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUjJR\|UxRTBwMEOwPVMh\|ryP	M17YNHNCVkeHUh?=
OVCAR-8	NXnLXI9tT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoDlTWM2OD1yLkCzNVA4KM7:TR?=	MWDTRW5ITVJ?
IMR-5	MkW1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFL6PVJKSzVyPUCuNFMzPDRizszN	Mmn1V2FPT0WU
DoTc2-4510	NGnJfGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHzQ[3RKSzVyPUCuNFM{QTNizszN	NFvzPGxUSU6JRWK=
HOS	MoLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWDMfXptUUN3ME2wMlA{PDd\|IN88US=>	M2rldXNCVkeHUh?=
HEC-1	NUfwWnJ3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlH2TWM2OD1yLkCzOlgh\|ryP	MVzTRW5ITVJ?
SW756	M123Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2noeWlEPTB;MD6wN\|gzOSEQvF2=	M2HoRnNCVkeHUh?=
NCI-H64	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHPFR4NKSzVyPUCuNFM5PDJizszN	NGTwd2xUSU6JRWK=
EW-16	NEjORY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUDN[Ip5UUN3ME2wMlA{QTB7IN88US=>	Mly2V2FPT0WU
CAL-51	MlHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4j1bmlEPTB;MD6wOFAxPSEQvF2=	MV3TRW5ITVJ?
KYSE-150	M2X5eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYjOUohPUUN3ME2wMlA1ODFzIN88US=>	NVy2dGFFW0GQR1XS
SW1710	NF7vSo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHK0foFKSzVyPUCuNFQxOThizszN	NYP6dohkW0GQR1XS
HuP-T4	Mlj2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUPJR\|UxRTBwMESxNVgh\|ryP	NWf2SFVUW0GQR1XS
LB373-MEL-D	MoDjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEHjT5pKSzVyPUCuNFQzOzJizszN	NX;YbY9lW0GQR1XS
EW-13	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4\5V2lEPTB;MD6wOFQxPiEQvF2=	MX;TRW5ITVJ?
HT-29	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVXJR\|UxRTBwMES0PUDPxE1?	NYrrS3Z4W0GQR1XS
SCC-25	MnTKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFTKUXRKSzVyPUCuNFQ1QTRizszN	NYrUZ2t6W0GQR1XS
REH	NHTkS\|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1XlTWlEPTB;MD6wOFY{PSEQvF2=	Ml63V2FPT0WU
L-363	NX;RN3UyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{D2UGlEPTB;MD6wOFY4QSEQvF2=	NYezNXd1W0GQR1XS
NCI-H1770	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mmj4TWM2OD1yLkC0Olk4KM7:TR?=	MoPlV2FPT0WU
CHL-1	NETXeVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIHtSJBKSzVyPUCuNFQ5PTdizszN	MmDQV2FPT0WU
ES1	M4r5PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYHJR\|UxRTBwMES4PFUh\|ryP	NFOzfIlUSU6JRWK=
SCC-15	M{n0e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlzmTWM2OD1yLkC0PVAzKM7:TR?=	Ml3MV2FPT0WU
MRK-nu-1	M{HIUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVrrWWg4UUN3ME2wMlA1QTN4IN88US=>	NEL0c3RUSU6JRWK=
PF-382	NWfSbZBFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEHXTIxKSzVyPUCuNFQ6OzlizszN	NULoW3FVW0GQR1XS
COLO-680N	MmPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYfJR\|UxRTBwMEWwOFch\|ryP	MUHTRW5ITVJ?
LK-2	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{DI[2lEPTB;MD6wOVA3OyEQvF2=	M2XH[XNCVkeHUh?=
NCI-H2342	MmPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX7RZnMyUUN3ME2wMlA2OTF5IN88US=>	M2n1[HNCVkeHUh?=
HMV-II	NIn2SFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEG0XVNKSzVyPUCuNFUzOzlizszN	NH[0WYJUSU6JRWK=
PC-14	M4HQPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MU\JR\|UxRTBwMEWyOVIh\|ryP	M1ywSnNCVkeHUh?=
COLO-320-HSR	NU\yOpNDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mnf4TWM2OD1yLkC1Nlg6KM7:TR?=	M13GeHNCVkeHUh?=
697	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEDRcWlKSzVyPUCuNFU{OjNizszN	MY\TRW5ITVJ?
NEC8	NWTGfIlET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MULJR\|UxRTBwMEW1PUDPxE1?	NGi0OVdUSU6JRWK=
LCLC-97TM1	MknBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkHOTWM2OD1yLkC1OVk1KM7:TR?=	M3niT3NCVkeHUh?=
Daoy	NGS1T2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MojQTWM2OD1yLkC1OlE3KM7:TR?=	M{j3T3NCVkeHUh?=
ETK-1	NUjmb5p7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3LSO2lEPTB;MD6wOVY4OiEQvF2=	NGjKdnhUSU6JRWK=
A388	MojRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4OyVGlEPTB;MD6wOVY6PSEQvF2=	Mn;qV2FPT0WU
COLO-205	M{Did2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUf2[XBsUUN3ME2wMlA2PzF4IN88US=>	M{LrWnNCVkeHUh?=
SK-PN-DW	MmD6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVnJR\|UxRTBwMEW3Nlkh\|ryP	M{e1OnNCVkeHUh?=
SF268	NVTxO5RHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUfJR\|UxRTBwMEW3OVYh\|ryP	NUm1VYJtW0GQR1XS
OCI-AML2	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkOzTWM2OD1yLkC1O\|c4KM7:TR?=	M3rZdHNCVkeHUh?=
GAMG	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXu1enRMUUN3ME2wMlA2QCEQvF2=	M2nZbHNCVkeHUh?=
BCPAP	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MojDTWM2OD1yLkC1PFkzKM7:TR?=	MluwV2FPT0WU
BC-1	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWnSR\|ZsUUN3ME2wMlA3ODJ{IN88US=>	M{H1UnNCVkeHUh?=
IA-LM	NXrOUWNVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlKzTWM2OD1yLkC2NFU{KM7:TR?=	M1zXb3NCVkeHUh?=
NCI-H1299	NYHETFl6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYHmepZDUUN3ME2wMlA3OTNizszN	NVjONY5QW0GQR1XS
COR-L23	NFTFXnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnXtTWM2OD1yLkC2NVM1KM7:TR?=	Mk\rV2FPT0WU
KYSE-180	NUf2fHpWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlXsTWM2OD1yLkC2NVQzKM7:TR?=	MXvTRW5ITVJ?
LOXIMVI	MkLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnT1TWM2OD1yLkC2NVg5KM7:TR?=	MofnV2FPT0WU
BL-41	NH[wdJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYTDfZZVUUN3ME2wMlA3OjF7IN88US=>	MYjTRW5ITVJ?
BL-70	M{PqOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWHONoZ2UUN3ME2wMlA3OzB{IN88US=>	MmC0V2FPT0WU
NOS-1	NUXFUlhvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUfaeHd6UUN3ME2wMlA3PDFzIN88US=>	MlXBV2FPT0WU
NB13	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUnJR\|UxRTBwME[0NlEh\|ryP	MXvTRW5ITVJ?
CAL-27	NFjpV25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUfJR\|UxRTBwME[0OlQh\|ryP	NWrVcpBmW0GQR1XS
CA46	NHXReHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mne3TWM2OD1yLkC2OVM4KM7:TR?=	MYXTRW5ITVJ?
SW962	MlrkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXnJR\|UxRTBwME[1Olkh\|ryP	NV;5fIM1W0GQR1XS
NCI-H226	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmjYTWM2OD1yLkC2OlMzKM7:TR?=	M2L6VHNCVkeHUh?=
KYSE-70	NHnROoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M33LbWlEPTB;MD6wOlk1PSEQvF2=	MYjTRW5ITVJ?
Daudi	NYjOfWZUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX3TO4o2UUN3ME2wMlA4ODhzIN88US=>	MVnTRW5ITVJ?
SW626	NEf1SoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVXJR\|UxRTBwMEeyNFQh\|ryP	MV3TRW5ITVJ?
ESS-1	NUPsNpduT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnH1TWM2OD1yLkC3NlQ3KM7:TR?=	M1e3Z3NCVkeHUh?=
YT	NHPre\|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXfJR\|UxRTBwMEezOFUh\|ryP	NH2zfZZUSU6JRWK=
P12-ICHIKAWA	NFrzSohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NITFSGxKSzVyPUCuNFc{PDlizszN	MnyxV2FPT0WU
BxPC-3	Ml;zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NU[2Wo8{UUN3ME2wMlA4PDV6IN88US=>	NHHvU5pUSU6JRWK=
CTV-1	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml7uTWM2OD1yLkC3OVE4KM7:TR?=	NE\UPIVUSU6JRWK=
MLMA	M{XsSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGLseWJKSzVyPUCuNFc2OzRizszN	MWLTRW5ITVJ?
WSU-NHL	NVfjUmdGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnPvTWM2OD1yLkC3OVU1KM7:TR?=	MVPTRW5ITVJ?
CTB-1	NWGz[FJsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYXJR\|UxRTBwMEe1PFgh\|ryP	MVjTRW5ITVJ?
MMAC-SF	Mo\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4PDV2lEPTB;MD6wO\|Y3QCEQvF2=	MXvTRW5ITVJ?
8-MG-BA	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWrJR\|UxRTBwMEe4NFEh\|ryP	MXvTRW5ITVJ?
NCI-H358	M3TBVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXzadZRJUUN3ME2wMlA4QDd7IN88US=>	MnrBV2FPT0WU
BFTC-905	M364[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlnjTWM2OD1yLkC3PVA6KM7:TR?=	M37tNXNCVkeHUh?=
NCI-H727	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGnGZWRKSzVyPUCuNFgxPTNizszN	M4r4NXNCVkeHUh?=
CHP-212	MkSwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUXLbpJjUUN3ME2wMlA5ODl3IN88US=>	NVu2cY1wW0GQR1XS
HOP-62	M2\URmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWTwVpRpUUN3ME2wMlA5OjR3IN88US=>	M3rqUnNCVkeHUh?=
CESS	M{Tae2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1TYe2lEPTB;MD6wPFI3QSEQvF2=	NEfqZmFUSU6JRWK=
HuCCT1	M4\abmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHXNUphKSzVyPUCuNFg{OzNizszN	Mmm4V2FPT0WU
DEL	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGjBdHlKSzVyPUCuNFg{PDdizszN	NEK4fmJUSU6JRWK=
5637	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{O2Z2lEPTB;MD6wPFM3PyEQvF2=	MWXTRW5ITVJ?
RS4-11	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHnrTpZKSzVyPUCuNFg1QTdizszN	M36xeXNCVkeHUh?=
KURAMOCHI	NWfuXVVyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnHjTWM2OD1yLkC4OVA6KM7:TR?=	NEeyV2RUSU6JRWK=
A427	M2Pn[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV\JR\|UxRTBwMEi1NVIh\|ryP	MWfTRW5ITVJ?
A3-KAW	M3rMPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFvGWYlKSzVyPUCuNFg2PjZizszN	NH\u[mhUSU6JRWK=
LS-123	MkDBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF[4TllKSzVyPUCuNFg4OTlizszN	NECxc3VUSU6JRWK=
LoVo	M4XkSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFX5XnpKSzVyPUCuNFg4OiEQvF2=	MnO1V2FPT0WU
PA-1	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mk\vTWM2OD1yLkC4O\|Y6KM7:TR?=	Mm\BV2FPT0WU
CP50-MEL-B	Ml3wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1S4NWlEPTB;MD6wPFc6OyEQvF2=	MYjTRW5ITVJ?
A431	M1XydWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFz2NZRKSzVyPUCuNFg5ODFizszN	NGHYTZNUSU6JRWK=
HCT-116	NEOyXGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NI\CelFKSzVyPUCuNFg5ODJizszN	M2fySnNCVkeHUh?=
A4-Fuk	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4fHZ2lEPTB;MD6wPFk1PyEQvF2=	NHj1bG1USU6JRWK=
RPMI-6666	M{LRfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVrJR\|UxRTBwMEi5Olch\|ryP	M162SnNCVkeHUh?=
Calu-6	NUjKUIQxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2mydmlEPTB;MD6wPVAzQSEQvF2=	NVnYfZcxW0GQR1XS
KMOE-2	NVTsUWoxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGG4XItKSzVyPUCuNFkxOzlizszN	Mle5V2FPT0WU
A704	M3nGOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlvoTWM2OD1yLkC5NVUh\|ryP	NIfXZopUSU6JRWK=
HO-1-N-1	NELo[2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXfBT3RPUUN3ME2wMlA6OjR7IN88US=>	NXLjOopRW0GQR1XS
NCI-H2122	NYfrZ4FJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVzJR\|UxRTBwMEmzO\|gh\|ryP	Mm\JV2FPT0WU
U-698-M	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2KzZ2lEPTB;MD6wPVQxQSEQvF2=	NEjzO3FUSU6JRWK=
IST-SL2	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYrZXXJNUUN3ME2wMlA6PDZ6IN88US=>	M3LLZXNCVkeHUh?=
TE-10	Ml;XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIHPfVdKSzVyPUCuNFk2QDRizszN	M1f2XHNCVkeHUh?=
PANC-03-27	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1jZdmlEPTB;MD6wPVY4OSEQvF2=	MX\TRW5ITVJ?
KYSE-410	NH3xfW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoHqTWM2OD1yLkC5O\|k4KM7:TR?=	MkXWV2FPT0WU
TE-8	M2[5XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYjJR\|UxRTBwMEm4PFUh\|ryP	M1vWcHNCVkeHUh?=
MN-60	M3ntVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUPJR\|UxRTBwMEm4PVch\|ryP	MYHTRW5ITVJ?
NCI-H460	NVm5cpo{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2O1TGlEPTB;MD6xNFA6KM7:TR?=	M1jIfnNCVkeHUh?=
LB771-HNC	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlHMTWM2OD1yLkGwNlU2KM7:TR?=	M3XycnNCVkeHUh?=
ES4	MoLaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXPJR\|UxRTBwMUCyOlQh\|ryP	NELWWG9USU6JRWK=
HUTU-80	NHrUcopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmXOTWM2OD1yLkGwN\|Y2KM7:TR?=	M2LnenNCVkeHUh?=
647-V	NFrBbZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVHJR\|UxRTBwMUC0NFgh\|ryP	NXnnNHI4W0GQR1XS
HTC-C3	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEXDTWxKSzVyPUCuNVA1OzJizszN	NXPXUGdSW0GQR1XS
NTERA-S-cl-D1	NUXJTGpqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlrETWM2OD1yLkGwOFQ5KM7:TR?=	MVXTRW5ITVJ?
A2058	M4rNU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYfJR\|UxRTBwMUC2OVUh\|ryP	M3fUWHNCVkeHUh?=
MZ1-PC	NH7aZpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlLHTWM2OD1yLkGwPFMh\|ryP	MUnTRW5ITVJ?
J82	MlzLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkWzTWM2OD1yLkGwPFg1KM7:TR?=	MnjtV2FPT0WU
ARH-77	NVO1XnRnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{jubWlEPTB;MD6xNUDPxE1?	M3;ndnNCVkeHUh?=
Ca9-22	NUPBSYNyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYH6SFNRUUN3ME2wMlEyOTJ6IN88US=>	MUjTRW5ITVJ?
NCI-H1648	NYPNRVVLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX\ud2hDUUN3ME2wMlEyOjh4IN88US=>	M2nQOXNCVkeHUh?=
MC116	MkjVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYrJR\|UxRTBwMUGzN\|ch\|ryP	M2jHSnNCVkeHUh?=
EoL-1-cell	M4jXWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1[yV2lEPTB;MD6xNVQ3PyEQvF2=	MlXVV2FPT0WU
PANC-10-05	NFXV[JhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFi0RmtKSzVyPUCuNVE1QTFizszN	MXzTRW5ITVJ?
SF539	M1jaOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml;rTWM2OD1yLkGxOlE3KM7:TR?=	MXzTRW5ITVJ?
ES8	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH3TXFBKSzVyPUCuNVE3OzNizszN	NH;ROGlUSU6JRWK=
NCI-H810	MkT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGL5R\|ZKSzVyPUCuNVE3PjRizszN	NI\2O2RUSU6JRWK=
J-RT3-T3-5	NUnXR4hFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWHJR\|UxRTBwMUG3OUDPxE1?	M3nmZ3NCVkeHUh?=
NY	NWnEUIdlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVnJR\|UxRTBwMUG4NVch\|ryP	MXnTRW5ITVJ?
NCI-SNU-1	M1:wV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4\WfWlEPTB;MD6xNlE1QCEQvF2=	NIDNXlVUSU6JRWK=
EFM-19	NGLOTVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVvSdFFmUUN3ME2wMlEzOzd2IN88US=>	NFq4bolUSU6JRWK=
HCC1806	M3zSSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NILLR\|dKSzVyPUCuNVI{QDNizszN	NGrtUotUSU6JRWK=
HCE-T	NV\me\|RjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4[5ZWlEPTB;MD6xNlU{OSEQvF2=	NEjHbHJUSU6JRWK=
HT-1376	NWW1dFRKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmTUTWM2OD1yLkGyOlY5KM7:TR?=	MmP6V2FPT0WU
BE-13	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWfJbHdpUUN3ME2wMlEzQDZ4IN88US=>	MluyV2FPT0WU
NCI-H520	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NI\TOJlKSzVyPUCuNVI5PjdizszN	M2nPe3NCVkeHUh?=
SK-MES-1	NI\vPVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGr4T21KSzVyPUCuNVI6OTNizszN	MWfTRW5ITVJ?
SNU-423	M1jBZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF:1UpBKSzVyPUCuNVI6OTRizszN	M2XFenNCVkeHUh?=
Ramos-2G6-4C10	M1W4OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHu2dIxKSzVyPUCuNVI6OTZizszN	NFz1NFJUSU6JRWK=
EW-18	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnfFTWM2OD1yLkGzNFI3KM7:TR?=	MWfTRW5ITVJ?
NCI-H2087	NH\1T3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml[zTWM2OD1yLkGzNFI4KM7:TR?=	NILq[pNUSU6JRWK=
COLO-792	NYHqbVRWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3HYbmlEPTB;MD6xN\|E3PSEQvF2=	NHn1bI5USU6JRWK=
QIMR-WIL	NXTW[HllT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4fnb2lEPTB;MD6xN\|IzOyEQvF2=	M1znb3NCVkeHUh?=
ACHN	NU\jSnUyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYHubpIyUUN3ME2wMlE{OjR5IN88US=>	NFL2[VdUSU6JRWK=
RPMI-8866	M1mwTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkfkTWM2OD1yLkGzNlYyKM7:TR?=	MYDTRW5ITVJ?
SK-LU-1	NXLwR\|J3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVPKfJE4UUN3ME2wMlE{PDR7IN88US=>	NVXVdZhsW0GQR1XS
SK-UT-1	NF30c5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUX0emNIUUN3ME2wMlE{PjJ6IN88US=>	MkX6V2FPT0WU
MFE-296	NYe5O4JST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{ny[mlEPTB;MD6xN\|g3PCEQvF2=	MnPGV2FPT0WU
RD	NV3tSoxqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUjhVG5QUUN3ME2wMlE{QTl5IN88US=>	NIfyZYZUSU6JRWK=
LS-411N	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX\sfHV4UUN3ME2wMlE1Ojl3IN88US=>	Ml7EV2FPT0WU
NCI-H747	MlXRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M33RUmlEPTB;MD6xOFMh\|ryP	NELudJpUSU6JRWK=
ES6	NVLYN3lrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHvHcG5KSzVyPUCuNVQ{PiEQvF2=	NYLFTZl7W0GQR1XS
TE-1	NFzGPI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGDRSGVKSzVyPUCuNVQ1ODdizszN	NWjQV4FJW0GQR1XS
SJSA-1	NX\Yb2o1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUnJR\|UxRTBwMUS3NFch\|ryP	MVzTRW5ITVJ?
NCI-H1355	M2HDd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnHzTWM2OD1yLkG1Nlk{KM7:TR?=	NFX6bGNUSU6JRWK=
HEL	NUK5b2JuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYXWfVZ1UUN3ME2wMlE2PDR5IN88US=>	M2T1PXNCVkeHUh?=
639-V	MlnZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NED1ZZlKSzVyPUCuNVU2QTZizszN	MknSV2FPT0WU
AN3-CA	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3q0NWlEPTB;MD6xOVY{QSEQvF2=	NYPwTHpEW0GQR1XS
SK-MEL-2	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlyxTWM2OD1yLkG1OlY5KM7:TR?=	NWHpflI{W0GQR1XS
SW872	MlnhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXm3TZh3UUN3ME2wMlE3ODR{IN88US=>	NX[5b2dWW0GQR1XS
DU-4475	M2\oXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYXOO49EUUN3ME2wMlE3OTZ{IN88US=>	M3q3cXNCVkeHUh?=
YKG-1	NF:2XHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF7hepZKSzVyPUCuNVYzPzNizszN	NIXMVZFUSU6JRWK=
GT3TKB	M170PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWjiO4JSUUN3ME2wMlE3Ojh\|IN88US=>	MXLTRW5ITVJ?
GB-1	NWTKbYdOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mm\ETWM2OD1yLkG2OFI1KM7:TR?=	Mo\QV2FPT0WU
KARPAS-422	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NITUe3ZKSzVyPUCuNVY2PzRizszN	NU\W[ZFyW0GQR1XS
ATN-1	M3G1Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MknjTWM2OD1yLkG2OlU3KM7:TR?=	M2P2ZnNCVkeHUh?=
HLE	NUTFPIV2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlT5TWM2OD1yLkG2PFc4KM7:TR?=	M1[2c3NCVkeHUh?=
D-542MG	Mm\pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYHzc\|gzUUN3ME2wMlE3QTh4IN88US=>	MX3TRW5ITVJ?
EB-3	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlftTWM2OD1yLkG3N\|Eh\|ryP	Moq1V2FPT0WU
HCC1143	MnW3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXXJR\|UxRTBwMUezPVYh\|ryP	M{TkfXNCVkeHUh?=
DJM-1	NFHicJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MU\JR\|UxRTBwMUe0OVEh\|ryP	Ml25V2FPT0WU
BT-474	NI\mSWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{HxcWlEPTB;MD6xO\|Q5QSEQvF2=	MonCV2FPT0WU
BB65-RCC	NXHybXVbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUPJR\|UxRTBwMUe1OFUh\|ryP	NUP5S2p1W0GQR1XS
NCI-H292	NYCyUmpkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX\2T3EyUUN3ME2wMlE4PjBzIN88US=>	MnO2V2FPT0WU
MKN28	NF;mPHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4D0SGlEPTB;MD6xO\|Y2OyEQvF2=	M4XyZ3NCVkeHUh?=
TK10	NXWzdod4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV20OYt6UUN3ME2wMlE4PzB{IN88US=>	NXXZXYF[W0GQR1XS
TYK-nu	NUPwWpF5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXfJR\|UxRTBwMUe5OFkh\|ryP	M3:ze3NCVkeHUh?=
8305C	NWrDXo15T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEXTeZdKSzVyPUCuNVc6PzFizszN	NFPUNHpUSU6JRWK=
MV-4-11	NYDj[os{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnrXTWM2OD1yLkG3PVc4KM7:TR?=	Moi3V2FPT0WU
NCI-H522	NIDJUFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MknvTWM2OD1yLkG4NFk1KM7:TR?=	NXfyPG83W0GQR1XS
Hs-578-T	M1WwdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3vrVmlEPTB;MD6xPFI6OiEQvF2=	NV7wS5l4W0GQR1XS
LCLC-103H	NWDnUZBjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3vEZmlEPTB;MD6xPFUzPyEQvF2=	MVPTRW5ITVJ?
MHH-ES-1	M{\Dfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2LqZ2lEPTB;MD6xPFYzQSEQvF2=	NGnNXlJUSU6JRWK=
NCI-H441	NVK3[ZhiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVLJR\|UxRTBwMUmxOFgh\|ryP	MX7TRW5ITVJ?
AM-38	MoDWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHTWXnpKSzVyPUCuNVkzOjVizszN	M3PmW3NCVkeHUh?=
SW1783	Mnm2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXvPNFZiUUN3ME2wMlE6OzB3IN88US=>	M3;BRnNCVkeHUh?=
SK-HEP-1	Mkm3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFnsS2tKSzVyPUCuNVk3OzdizszN	MUjTRW5ITVJ?
OAW-28	MknjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXXJR\|UxRTBwMkCxO\|gh\|ryP	NFjVPW9USU6JRWK=
TE-15	M{Drb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkTYTWM2OD1yLkKwNlUzKM7:TR?=	NVWz[IFYW0GQR1XS
HCE-4	NYnQd2h2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnrYTWM2OD1yLkKwNlg1KM7:TR?=	NFznO4JUSU6JRWK=
JiyoyeP-2003	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV30fYZqUUN3ME2wMlIxOzN4IN88US=>	NUXXVFBtW0GQR1XS
OVCAR-4	NF\PRVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3vQdmlEPTB;MD6yNFYzQCEQvF2=	M2HP[XNCVkeHUh?=
SNU-449	MlHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml;aTWM2OD1yLkKwO\|k4KM7:TR?=	M3jseHNCVkeHUh?=
SBC-5	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2K2RmlEPTB;MD6yNVIyPSEQvF2=	M1GzdnNCVkeHUh?=
T84	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFXrSZFKSzVyPUCuNlEzPDhizszN	NEPtUYhUSU6JRWK=
LP-1	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVrxXnY2UUN3ME2wMlIyOzB{IN88US=>	NXvTO5Y2W0GQR1XS
MG-63	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnLGTWM2OD1yLkKxN\|gzKM7:TR?=	M3GyXnNCVkeHUh?=
OAW-42	MlKwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX2yZY5zUUN3ME2wMlIyPDd6IN88US=>	MXXTRW5ITVJ?
L-540	M3LJRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYLJR\|UxRTBwMkG1PVgh\|ryP	M4r3TnNCVkeHUh?=
RH-1	M1LCdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mnz6TWM2OD1yLkKyNlQzKM7:TR?=	Mn\RV2FPT0WU
HCT-15	MkD4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3XCW2lEPTB;MD6yNlQ5PCEQvF2=	MXTTRW5ITVJ?
OCUB-M	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mk\mTWM2OD1yLkKyOFg5KM7:TR?=	MofrV2FPT0WU
GP5d	NIfkVmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV7BfllGUUN3ME2wMlIzPTJ6IN88US=>	NUm3bmpFW0GQR1XS
NCI-H2030	Mn\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mkm3TWM2OD1yLkKyO\|M1KM7:TR?=	NV3pelh2W0GQR1XS
ML-2	NWXxUXduT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4TveWlEPTB;MD6yNlg5QSEQvF2=	MmfjV2FPT0WU
CAL-39	NYOzNoNkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmfvTWM2OD1yLkKyPVM3KM7:TR?=	M2DOeHNCVkeHUh?=
MIA-PaCa-2	MkW3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnPBTWM2OD1yLkKzNlg4KM7:TR?=	Mn:1V2FPT0WU
TE-9	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1\4c2lEPTB;MD6yN\|MzKM7:TR?=	NFHrcnlUSU6JRWK=
LB2518-MEL	MlLvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXy0Z2FqUUN3ME2wMlI{Ozd{IN88US=>	MW\TRW5ITVJ?
DB	NUHw[4NnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYrJR\|UxRTBwMkO0N\|gh\|ryP	MVHTRW5ITVJ?
NCI-H596	NVHzWpNNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV30OY1JUUN3ME2wMlI{PTdzIN88US=>	M1T2bXNCVkeHUh?=
SW1990	NYPZVJRST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnXaTWM2OD1yLkKzPVQ3KM7:TR?=	NWnLbW5JW0GQR1XS
P30-OHK	M2nVUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEmxR3dKSzVyPUCuNlQxPSEQvF2=	M3;ue3NCVkeHUh?=
ALL-PO	NETlfIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYfBSmhjUUN3ME2wMlI1OTZ7IN88US=>	Ml3vV2FPT0WU
Saos-2	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoniTWM2OD1yLkK0OVcyKM7:TR?=	M2[zOXNCVkeHUh?=
MFH-ino	NILDZotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoSwTWM2OD1yLkK0OlkzKM7:TR?=	NYDvSGZSW0GQR1XS
OE33	NVHQelhTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2i0UWlEPTB;MD6yOVEyKM7:TR?=	M{XOXHNCVkeHUh?=
Calu-3	NVTlcYQxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVvHXHJmUUN3ME2wMlI2Ojl5IN88US=>	NF;kNGhUSU6JRWK=
HT	NV\aU4tXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYTud5JDUUN3ME2wMlI2PjJzIN88US=>	NG[wWmZUSU6JRWK=
LXF-289	NWjQV2Z5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIDyVndKSzVyPUCuNlU6QDRizszN	MkfFV2FPT0WU
KGN	NYPlNGF7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWHGT3lGUUN3ME2wMlI3ODh7IN88US=>	M3nUOnNCVkeHUh?=
NCI-H1417	NYHT[GsxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYXJR\|UxRTBwMk[1NlQh\|ryP	MYXTRW5ITVJ?
SF126	NHG2[ZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4HYd2lEPTB;MD6yO\|MxOiEQvF2=	MWfTRW5ITVJ?
SAS	NF;ROplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoK0TWM2OD1yLkK3N\|A5KM7:TR?=	MXLTRW5ITVJ?
22RV1	NWfY[3NqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn3pTWM2OD1yLkK3N\|c5KM7:TR?=	MWHTRW5ITVJ?
GI-1	MoTPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHzhbFRKSzVyPUCuNlc1QDdizszN	NWDI[lNoW0GQR1XS
ES3	M{Pnemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWXJR\|UxRTBwMke3OlMh\|ryP	NWLlZ\|ZHW0GQR1XS
NB1	Mn\YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml3ZTWM2OD1yLkK3PFc3KM7:TR?=	NIrvdmZUSU6JRWK=
NCI-H650	M4HufGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIfvUYlKSzVyPUCuNlg{ODJizszN	M4f3eHNCVkeHUh?=
IST-MES1	M4rPSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXnlNVZTUUN3ME2wMlI5PTV2IN88US=>	NFzJVYdUSU6JRWK=
UM-UC-3	NVjHfJRIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2DJZWlEPTB;MD6yPVE1KM7:TR?=	MUTTRW5ITVJ?
CAL-120	M2nKfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4L2[WlEPTB;MD6yPVY{OSEQvF2=	MXPTRW5ITVJ?
UACC-62	NUf3ZnpbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4rxOmlEPTB;MD6zNFI1OSEQvF2=	MlXoV2FPT0WU
TE-11	M161c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFLTSZBKSzVyPUCuN\|AzPDlizszN	NF;JZY5USU6JRWK=
MKN1	NUT0NJhNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWnJR\|UxRTBwM{CzOkDPxE1?	MmKxV2FPT0WU
KS-1	NVfOPYNyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXHVcGY4UUN3ME2wMlMxPTJ4IN88US=>	M2HROnNCVkeHUh?=
GCIY	M3nIOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUPJR\|UxRTBwM{GwNFIh\|ryP	NGTTVZRUSU6JRWK=
OVCAR-5	NEH5fGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVfJR\|UxRTBwM{GxNFYh\|ryP	MoLOV2FPT0WU
U-266	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEHhZmZKSzVyPUCuN\|EyPDdizszN	M2XGd3NCVkeHUh?=
Calu-1	MlzYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3nuNGlEPTB;MD6zNVI5QSEQvF2=	MkG1V2FPT0WU
SK-LMS-1	NYWyW\|U2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWfJR\|UxRTBwM{G0Nlkh\|ryP	MnfXV2FPT0WU
COLO-741	M1\tSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWPkd\|lRUUN3ME2wMlMyPjF2IN88US=>	MYDTRW5ITVJ?
RPMI-8226	NWfZd2xmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4PZTWlEPTB;MD6zNVY1OSEQvF2=	NF3IWIxUSU6JRWK=
KM12	NU\pdFJQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXfJR\|UxRTBwM{G4N{DPxE1?	MoLBV2FPT0WU
NMC-G1	M1rEUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXnjeJlHUUN3ME2wMlMyQDZizszN	NXj6[WROW0GQR1XS
SJRH30	NX;HXoJxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M32zNmlEPTB;MD6zNlA2OiEQvF2=	MoDwV2FPT0WU
COR-L105	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXLJR\|UxRTBwM{KyNVgh\|ryP	NVfIZ\|I5W0GQR1XS
IM-9	NXi2XmZYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYPrb49EUUN3ME2wMlM{ODJzIN88US=>	NIrGZYNUSU6JRWK=
TE-12	NWrMfW43T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUX4XFdOUUN3ME2wMlM{OzF5IN88US=>	MWnTRW5ITVJ?
KG-1	M1nEPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWjCS2VPUUN3ME2wMlM{PDN{IN88US=>	NWLmcVN{W0GQR1XS
U251	NHHhXZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnziTWM2OD1yLkOzOFU3KM7:TR?=	MUTTRW5ITVJ?
EFO-27	M4HRR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHvkZ5pKSzVyPUCuN\|M6PTFizszN	NYjRb4F{W0GQR1XS
EW-24	M13nOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2fK[WlEPTB;MD6zN\|k5PCEQvF2=	MVHTRW5ITVJ?
SF295	NXL6boNKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnfXTWM2OD1yLkOzPVk6KM7:TR?=	NXPnNXZnW0GQR1XS
MC-IXC	NG\LSoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3XVfWlEPTB;MD6zOFUh\|ryP	NHLTfVdUSU6JRWK=
NCI-H2405	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUnJR\|UxRTBwM{S3N\|Ih\|ryP	MnPUV2FPT0WU
NCI-H2009	MkT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml\STWM2OD1yLkO0O\|M6KM7:TR?=	MX3TRW5ITVJ?
LB1047-RCC	NVS4eYp7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXjJR\|UxRTBwM{W4NVUh\|ryP	Ml7LV2FPT0WU
KNS-81-FD	Mlv3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUDJR\|UxRTBwM{[2Olch\|ryP	NVLJSHdWW0GQR1XS
HOP-92	M1fjV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEXy[FlKSzVyPUCuN\|Y5OyEQvF2=	Mn[zV2FPT0WU
L-428	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXPJR\|UxRTBwM{ewNVYh\|ryP	MUTTRW5ITVJ?
C3A	NYHXSWZCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{XVfmlEPTB;MD6zO\|M4QSEQvF2=	NYDCPGJEW0GQR1XS
NCI-H1792	MnHWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVy3c\|JYUUN3ME2wMlM4PjV3IN88US=>	MnHaV2FPT0WU
HuH-7	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHOyTIRKSzVyPUCuN\|c6OSEQvF2=	NFTNWoJUSU6JRWK=
AGS	NVT5UnZ7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M135eGlEPTB;MD6zPFY{QCEQvF2=	NIrxeVhUSU6JRWK=
HT-1197	M4j2SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1nrZWlEPTB;MD6zPVQ3KM7:TR?=	NGDBco1USU6JRWK=
CGTH-W-1	M1vJ[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEXUVWhKSzVyPUCuN\|k6OTNizszN	NF;HTnpUSU6JRWK=
KNS-42	MmD6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn[yTWM2OD1yLkSwNFQ2KM7:TR?=	M1TOT3NCVkeHUh?=
HuO-3N1	NIfCUINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV3JR\|UxRTBwNECwOVUh\|ryP	NXfnSWlVW0GQR1XS
VMRC-RCZ	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NU[1eFZ{UUN3ME2wMlQxOzB\|IN88US=>	MknkV2FPT0WU
SW954	M33N[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnLZTWM2OD1yLkSwN\|M2KM7:TR?=	M2LhSnNCVkeHUh?=
MES-SA	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4O5U2lEPTB;MD60NFUxPSEQvF2=	NFTEO49USU6JRWK=
Ca-Ski	M{frT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2DJXmlEPTB;MD60NFUzPCEQvF2=	NWfWVpptW0GQR1XS
SW13	M1O5[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUPJR\|UxRTBwNEC2NlYh\|ryP	NHOzTXlUSU6JRWK=
NCI-H1437	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWnJR\|UxRTBwNEC4NFUh\|ryP	M4nFWXNCVkeHUh?=
U-118-MG	M{Gzemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIS3[oZKSzVyPUCuOFA6ODRizszN	MWTTRW5ITVJ?
NCI-H1734	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX\nSXkxUUN3ME2wMlQzODF\|IN88US=>	MVjTRW5ITVJ?
HDLM-2	M2O5NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoDWTWM2OD1yLkSyNFM{KM7:TR?=	NVrXSmJ4W0GQR1XS
AU565	NFHkW\|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXXWZo9lUUN3ME2wMlQzPDZ6IN88US=>	MkjEV2FPT0WU
FADU	M1Lh[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGTuSW1KSzVyPUCuOFI3PDlizszN	MXnTRW5ITVJ?
OS-RC-2	MlS4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXj0dnJRUUN3ME2wMlQ{ODh\|IN88US=>	NEi3N2ZUSU6JRWK=
CAMA-1	NHvrSWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVPJR\|UxRTBwNEO2NlYh\|ryP	NEnZPWpUSU6JRWK=
MONO-MAC-6	NHmzUotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH3NcnBKSzVyPUCuOFM5PDlizszN	NYXQ[mtOW0GQR1XS
LB831-BLC	M3e2d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3HuRmlEPTB;MD60OFM4OSEQvF2=	NUjDNJAzW0GQR1XS
SW982	M{HyVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWXiS4NCUUN3ME2wMlQ1PTJ6IN88US=>	NUjzU5c2W0GQR1XS
SCC-3	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUHJR\|UxRTBwNES1O\|kh\|ryP	MUfTRW5ITVJ?
C32	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVPJR\|UxRTBwNEWyNlkh\|ryP	NXHlRllIW0GQR1XS
BFTC-909	NFu3[VJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2KyVWlEPTB;MD60OVI6QSEQvF2=	NFzkVG5USU6JRWK=
MEG-01	M3rPOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlPLTWM2OD1yLkS1N\|c{KM7:TR?=	MWjTRW5ITVJ?
M14	NHnVSFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXzRe2tZUUN3ME2wMlQ2QTd7IN88US=>	NWn4[5pCW0GQR1XS
MPP-89	NXjtUWVLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml;0TWM2OD1yLkS2NlU3KM7:TR?=	NUPxcXM1W0GQR1XS
HCC1937	MnvQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnG0TWM2OD1yLkS2N\|g1KM7:TR?=	MWjTRW5ITVJ?
SW837	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGfCO3pKSzVyPUCuOFY4OjJizszN	M{TjdXNCVkeHUh?=
DU-145	NXrDO5czT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYT1VlBqUUN3ME2wMlQ3PzJ7IN88US=>	NYX3Z\|lUW0GQR1XS
LB996-RCC	M2\vfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHnIeZVKSzVyPUCuOFcxPTRizszN	MYPTRW5ITVJ?
C8166	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVe4TppnUUN3ME2wMlQ4PCEQvF2=	MUHTRW5ITVJ?
MOLT-4	NEX2[VlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH;LVYlKSzVyPUCuOFc4OzRizszN	MoPRV2FPT0WU
DMS-53	MlG0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYnKeoZIUUN3ME2wMlQ4QDB7IN88US=>	M2L2TXNCVkeHUh?=
TE-5	MlnMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUjZeGt6UUN3ME2wMlQ5OzB3IN88US=>	NVPOc3FtW0GQR1XS
KYSE-520	M3O4TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MljSTWM2OD1yLkS4N\|Q{KM7:TR?=	NVrpfm9EW0GQR1XS
Detroit562	M3z6bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUf4ToVVUUN3ME2wMlQ5QDZizszN	NUXPNmVYW0GQR1XS
SIMA	MoK5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFHDNopKSzVyPUCuOFk1OTdizszN	M3fnUnNCVkeHUh?=
NCI-H1651	M2f6[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHnTenZKSzVyPUCuOFk3PyEQvF2=	NI\leHhUSU6JRWK=
HCC1599	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MojmTWM2OD1yLkS5PVU2KM7:TR?=	M3LK[XNCVkeHUh?=
ABC-1	NF;uOZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUXJR\|UxRTBwNUC0PVYh\|ryP	MYnTRW5ITVJ?
CAL-33	Mmm2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFq4XWFKSzVyPUCuOVA5PDRizszN	MWPTRW5ITVJ?
OPM-2	M174T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVTJR\|UxRTBwNUC5N\|ch\|ryP	M2i1U3NCVkeHUh?=
RPMI-7951	MnrRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYXJR\|UxRTBwNUC5OVch\|ryP	NXHxfFgzW0GQR1XS
HT-1080	M3jmV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYPjZXA3UUN3ME2wMlUyOTF7IN88US=>	MmPQV2FPT0WU
LC4-1	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2DGUGlEPTB;MD61NVQxOyEQvF2=	MYLTRW5ITVJ?
OVCAR-3	M{HkVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX\BS5lyUUN3ME2wMlUyPTdizszN	MnW0V2FPT0WU
CAPAN-1	NXy5dXJ5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2XoRWlEPTB;MD61NlI5QCEQvF2=	NIDRRZZUSU6JRWK=
SK-OV-3	MlyyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4Px[GlEPTB;MD61NlQ{PCEQvF2=	NVv4UoNXW0GQR1XS
HuP-T3	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkDZTWM2OD1yLkWyPFI4KM7:TR?=	NVr0clI{W0GQR1XS
NCI-H838	NX63XIJzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV3JR\|UxRTBwNUK4OFkh\|ryP	MV3TRW5ITVJ?
K5	M3fNZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEHrRoxKSzVyPUCuOVMzODFizszN	M1jKfnNCVkeHUh?=
CAL-72	M3X0N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIHTXJRKSzVyPUCuOVM{QDdizszN	MX7TRW5ITVJ?
NH-12	M3fYcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWq3RVF7UUN3ME2wMlU{QTV7IN88US=>	NHnCPIZUSU6JRWK=
SNB75	M1LaN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4jjdmlEPTB;MD61OVc{KM7:TR?=	NEj2WZNUSU6JRWK=
BPH-1	NH7RT41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEHKe5NKSzVyPUCuOVY{PDRizszN	NVfSRZNOW0GQR1XS
NOMO-1	MknyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{PDSGlEPTB;MD61OlM4OiEQvF2=	NVXyU4tlW0GQR1XS
G-402	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYnCdIRtUUN3ME2wMlU3PDl7IN88US=>	MXHTRW5ITVJ?
NCI-H2052	M2GyTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX7JR\|UxRTBwNU[3OFEh\|ryP	MVrTRW5ITVJ?
RCM-1	NGPKS\|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkHRTWM2OD1yLkW3NVY3KM7:TR?=	NXrv[VVzW0GQR1XS
COR-L279	NUTJXIdrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnrHTWM2OD1yLkW3NVg2KM7:TR?=	MojrV2FPT0WU
A253	M1[xZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUjXWo45UUN3ME2wMlU4PTJ3IN88US=>	NGftOIJUSU6JRWK=
SK-MM-2	M1rhN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnXoTWM2OD1yLkW3Olc6KM7:TR?=	M1vnfXNCVkeHUh?=
NCI-H1703	M4XWUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4LJfWlEPTB;MD61PVQzPyEQvF2=	NWr6Oml7W0GQR1XS
UACC-257	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUPJR\|UxRTBwNUm0PFch\|ryP	M4P6fXNCVkeHUh?=
KALS-1	M2fsZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3jSfmlEPTB;MD62NFAyOSEQvF2=	MX\TRW5ITVJ?
ES5	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4XRcmlEPTB;MD62NFQ5KM7:TR?=	MXvTRW5ITVJ?
MHH-CALL-2	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml;ZTWM2OD1yLk[wPFg5KM7:TR?=	MWnTRW5ITVJ?
ChaGo-K-1	NGLkNoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGnIeIlKSzVyPUCuOlEzOjlizszN	NHTjNoVUSU6JRWK=
TGBC1TKB	NGToblFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mlu3TWM2OD1yLk[xPVgh\|ryP	NYTwdmpIW0GQR1XS
KU-19-19	Mly4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mnz1TWM2OD1yLk[0OVg3KM7:TR?=	MkPBV2FPT0WU
COLO-684	NGHSUVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYjJR\|UxRTBwNkW2NVEh\|ryP	MnnBV2FPT0WU
LS-1034	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MonnTWM2OD1yLk[1PFE6KM7:TR?=	NEjZcopUSU6JRWK=
RT-112	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFviOlBKSzVyPUCuOlY2QDdizszN	M2nFenNCVkeHUh?=
Capan-2	MkDnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEnqeYlKSzVyPUCuOlY3OjJizszN	MYjTRW5ITVJ?
HSC-4	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3L1[mlEPTB;MD62OlY6QCEQvF2=	NYfFfJhEW0GQR1XS
COLO-824	NHfhSVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXf1e3pUUUN3ME2wMlY4QDJ\|IN88US=>	NX;aNY16W0GQR1XS
NCI-H2170	NHLUdmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX\hWoVnUUN3ME2wMlY5OjV6IN88US=>	MXTTRW5ITVJ?
GDM-1	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoTwTWM2OD1yLk[4OFk1KM7:TR?=	NEK2W4pUSU6JRWK=
KP-4	Moe0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUfJR\|UxRTBwNkm1O\|Mh\|ryP	MnfCV2FPT0WU
VA-ES-BJ	MkHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGfSTGdKSzVyPUCuOlk6QDZizszN	MYfTRW5ITVJ?
KM-H2	Mk\IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MULJR\|UxRTBwN{CwPVEh\|ryP	MmjDV2FPT0WU
HH	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYfJR\|UxRTBwN{C2OlIh\|ryP	MknsV2FPT0WU
DK-MG	NV7FTGZ6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2DjWmlEPTB;MD63NVAyPiEQvF2=	MkP5V2FPT0WU
VM-CUB-1	MnvoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGjmT4hKSzVyPUCuO\|EzPTlizszN	NHTrdmpUSU6JRWK=
COLO-829	NGCwTWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mmn2TWM2OD1yLkexPVg2KM7:TR?=	MlzwV2FPT0WU
OMC-1	NU\ocVcyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoO5TWM2OD1yLkeyNVA1KM7:TR?=	NVznVlhnW0GQR1XS
NB12	NFjjW2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3;JRmlEPTB;MD63NlUxPCEQvF2=	MnGzV2FPT0WU
NCI-H28	M3\RdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MljOTWM2OD1yLke0NFg{KM7:TR?=	MkXLV2FPT0WU
A673	M2izeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3:zRWlEPTB;MD63OVE4PyEQvF2=	NGDzOIlUSU6JRWK=
LB2241-RCC	NYDBd5hST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVjJR\|UxRTBwN{[wPFch\|ryP	NX3UbIViW0GQR1XS
CCRF-CEM	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGjEbppKSzVyPUCuO\|cxPTJizszN	MlvaV2FPT0WU
NCI-H510A	M1G5dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3vaPWlEPTB;MD63O\|E5PiEQvF2=	NGHz[GtUSU6JRWK=
SW48	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkSwTWM2OD1yLke3N\|M{KM7:TR?=	NFW1XFBUSU6JRWK=
NCI-H2081	NYrkXWZ7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEHDVXRKSzVyPUCuO\|gyPDdizszN	M1;LN3NCVkeHUh?=
RMG-I	NHzqOJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1f4W2lEPTB;MD63PFIyOiEQvF2=	MlLxV2FPT0WU
LU-99A	MmTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mmr3TWM2OD1yLke4OFE{KM7:TR?=	NYX2dWVMW0GQR1XS
KP-N-YS	Mmj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX\UbXZmUUN3ME2wMlc5QTJzIN88US=>	MoTrV2FPT0WU
MDA-MB-231	M135TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVLJR\|UxRTBwOECxN\|Eh\|ryP	MmLQV2FPT0WU
U031	NVf1[WlZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUfiemNXUUN3ME2wMlgyPDJ\|IN88US=>	NXzkfZl7W0GQR1XS
EVSA-T	NHnGRXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1zVOWlEPTB;MD64NVY4OiEQvF2=	MnTTV2FPT0WU
MDA-MB-157	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWjEdIhJUUN3ME2wMlgzOjdzIN88US=>	NVTH[mhuW0GQR1XS
EHEB	NYX5[lVQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3jTfWlEPTB;MD64NlI4PiEQvF2=	M2PWbHNCVkeHUh?=
KINGS-1	MmDwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVrJR\|UxRTBwOEK1OVUh\|ryP	M{DvU3NCVkeHUh?=
23132-87	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mk[yTWM2OD1yLkiyPFQ{KM7:TR?=	M3\TNXNCVkeHUh?=
EFO-21	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHvmXWZKSzVyPUCuPFQxQDlizszN	MkC5V2FPT0WU
DOK	MmH5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXLKOG9pUUN3ME2wMlg1QCEQvF2=	M{\CTXNCVkeHUh?=
NCI-H2171	NUTueodRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnXwTWM2OD1yLki0PVYh\|ryP	MYjTRW5ITVJ?
NCI-SNU-5	Ml7GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NInhT2RKSzVyPUCuPFU2PyEQvF2=	NIK0eHdUSU6JRWK=
SK-N-DZ	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGHiSVlKSzVyPUCuPFU6PDNizszN	M1rIbXNCVkeHUh?=
SNU-C2B	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnPaTWM2OD1yLki2PFAyKM7:TR?=	MoHLV2FPT0WU
CP66-MEL	MoTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWjJR\|UxRTBwOEexNUDPxE1?	M{\KNHNCVkeHUh?=
SN12C	M2nWZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{OwdGlEPTB;MD64PFY{PyEQvF2=	MV;TRW5ITVJ?
A172	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3v6c2lEPTB;MD64PFY6QCEQvF2=	MYTTRW5ITVJ?
NCI-H2347	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVvJR\|UxRTBwOEi3OVMh\|ryP	M4rlSHNCVkeHUh?=
NCI-H2228	MnvPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFPTSpBKSzVyPUCuPFk{OzlizszN	MlH3V2FPT0WU
SNU-387	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Moj6TWM2OD1yLkmwNlY1KM7:TR?=	NHHHdWdUSU6JRWK=
SK-MEL-24	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXfHVnhjUUN3ME2wMlkyOzR2IN88US=>	M1TWVHNCVkeHUh?=
MDA-MB-468	MlzDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlS2TWM2OD1yLkmxO\|Mh\|ryP	NYT6SYdVW0GQR1XS
NCI-H1694	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn\ZTWM2OD1yLkmxPFc3KM7:TR?=	MY\TRW5ITVJ?
CCF-STTG1	M4XmWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIG4R3NKSzVyPUCuPVI3OzdizszN	NEH5fZJUSU6JRWK=
K052	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3XCc2lEPTB;MD65OFA1PyEQvF2=	M{DN[nNCVkeHUh?=
NCI-H446	MlixS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUD4e3hNUUN3ME2wMlk2ODFizszN	Ml7TV2FPT0WU
MFE-280	NEfZZ3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX\JR\|UxRTBwOU[yPVEh\|ryP	NGH6XY9USU6JRWK=
KU812	Mm\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYf3W2tvUUN3ME2wMlk6Ozh7IN88US=>	MW\TRW5ITVJ?
MDA-MB-361	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHyycZFKSzVyPUCuPVk4PzdizszN	NXzNb2lMW0GQR1XS
Raji	M3:y[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1XxT2lEPTB;MT6wNlI3PyEQvF2=	MXnTRW5ITVJ?
TE-6	NXzjeY14T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4X3PWlEPTB;MT6wN\|U3PiEQvF2=	NFnoWnNUSU6JRWK=
CAL-148	M4XXVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX3YcmNMUUN3ME2xMlA1PDR\|IN88US=>	NX;J[YhkW0GQR1XS
NCI-H1963	NYOwbZNNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWHE[HdRUUN3ME2xMlA1PTV\|IN88US=>	M3XtZ3NCVkeHUh?=
SK-N-AS	NUnt[XFGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYGz[GZ2UUN3ME2xMlA1Pjh3IN88US=>	NEGybJFUSU6JRWK=
RERF-LC-MS	NXrhbG5NT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1jHZWlEPTB;MT6wOlM1QSEQvF2=	NHLu[3VUSU6JRWK=
BEN	NXPI[WdFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlTsTWM2OD1zLkC3NVM4KM7:TR?=	NXXLepBlW0GQR1XS
CAS-1	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYnJR\|UxRTFwMEmxNlMh\|ryP	M1XJeHNCVkeHUh?=
SW780	NHW0NohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2WwZWlEPTB;MT6wPVE5OSEQvF2=	NYDjTYN3W0GQR1XS
LU-65	NUSydow3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2HiVmlEPTB;MT6wPVQyKM7:TR?=	MXLTRW5ITVJ?
D-283MED	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHPjXXZKSzVyPUGuNVIzPzJizszN	M1Hs[HNCVkeHUh?=
HCC2157	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYjJR\|UxRTFwMUO2OFIh\|ryP	NYTXWVUxW0GQR1XS
RCC10RGB	M2[2bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVHt[ZM6UUN3ME2xMlE1ODB4IN88US=>	Mn;NV2FPT0WU
PLC-PRF-5	NE\SOZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF;Jb\|NKSzVyPUGuNVUzOjlizszN	MUfTRW5ITVJ?
H4	NYLU[HIzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M132XmlEPTB;MT6xOVQ{QSEQvF2=	NIWxNnJUSU6JRWK=
TUR	NEPtbJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoLuTWM2OD1zLkG1O\|UzKM7:TR?=	NYf1cJlwW0GQR1XS
NCI-H2141	Mn7nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnPYTWM2OD1zLkG4PVQ3KM7:TR?=	MoXPV2FPT0WU
PFSK-1	M4[2O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWq4TGFTUUN3ME2xMlIxPTN{IN88US=>	MXjTRW5ITVJ?
SK-MEL-28	NWC3Nm06T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWPWWVd2UUN3ME2xMlI{OjJzIN88US=>	MoLiV2FPT0WU
SCC-9	MkfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmXtTWM2OD1zLkKzOlY2KM7:TR?=	MoCyV2FPT0WU
T47D	NFvCdVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEXXNZVKSzVyPUGuNlM3QTZizszN	MXfTRW5ITVJ?
TCCSUP	M2jVN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUe4SG45UUN3ME2xMlI2ODJ7IN88US=>	MYjTRW5ITVJ?
SU-DHL-1	NF:0eVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWPJR\|UxRTFwMkWxNVgh\|ryP	MVLTRW5ITVJ?
HL-60	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoGzTWM2OD1zLkK1OVg5KM7:TR?=	M3fIT3NCVkeHUh?=
NCI-H1436	NHjlOGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUDUNHFqUUN3ME2xMlI3OTR7IN88US=>	MXrTRW5ITVJ?
DMS-114	M17WcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3nObWlEPTB;MT6yOlY{OiEQvF2=	Mkf0V2FPT0WU
BOKU	NXrvZmg4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mmf4TWM2OD1zLkK4NFk2KM7:TR?=	M1jJVXNCVkeHUh?=
MS-1	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX\JR\|UxRTFwMkmwOlkh\|ryP	NXfF[mVJW0GQR1XS
NCI-H661	NWraephvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWfJR\|UxRTFwM{C0O\|gh\|ryP	M1zqWXNCVkeHUh?=
HT-3	NFnpcW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnnWTWM2OD1zLkOwOVI6KM7:TR?=	NGLYZ\|ZUSU6JRWK=
CAL-54	NW\2NolQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGHBNWlKSzVyPUGuN\|A4OjVizszN	MmW4V2FPT0WU
SW1463	NYPMSoxWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUPxPYxDUUN3ME2xMlMyQDd{IN88US=>	M4Czb3NCVkeHUh?=
COLO-668	NUmwdlJbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGDve4dKSzVyPUGuN\|MxPTZizszN	MWjTRW5ITVJ?
PANC-08-13	M2TnV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUPJR\|UxRTFwM{O4NFMh\|ryP	M3f3UXNCVkeHUh?=
BB49-HNC	NWPleJduT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlSzTWM2OD1zLkO0NFEh\|ryP	M32xVHNCVkeHUh?=
M059J	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWnJR\|UxRTFwM{W4N\|Ih\|ryP	MmPxV2FPT0WU
NCCIT	NIDDNHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{T3ZWlEPTB;MT6zO\|k5QCEQvF2=	MnG5V2FPT0WU
LN-405	NHLTVWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFHvUFVKSzVyPUGuN\|kzPjRizszN	Mn7mV2FPT0WU
UMC-11	M2\0Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{P1OWlEPTB;MT6zPVk6PiEQvF2=	Mo[zV2FPT0WU
NB5	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGDKS\|lKSzVyPUGuOFEzOjdizszN	NYjENFZQW0GQR1XS
TE-441-T	M1yzSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH\FXYNKSzVyPUGuOFI5OTdizszN	MVnTRW5ITVJ?
ME-180	M3PJe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVPUOIdiUUN3ME2xMlQ1Ozl{IN88US=>	MVjTRW5ITVJ?
HCC70	M3r1W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1TWSGlEPTB;MT60OlA6PiEQvF2=	M4nVZXNCVkeHUh?=
no-10	MoPLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVTJR\|UxRTFwNE[xPFEh\|ryP	MlHBV2FPT0WU
JEG-3	NI\qd4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlfITWM2OD1zLkWwNVMzKM7:TR?=	NGLLNZhUSU6JRWK=
no-11	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIL2SllKSzVyPUGuOVA5QDJizszN	NYL2[XhzW0GQR1XS
CHP-126	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWjJR\|UxRTFwNU[2PVEh\|ryP	MUPTRW5ITVJ?
EGI-1	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M13Ee2lEPTB;MT61PFAzPSEQvF2=	NHrzNoVUSU6JRWK=
D-392MG	NEXOZnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnfsTWM2OD1zLkW5OlMh\|ryP	MYHTRW5ITVJ?
RT4	MoXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MonwTWM2OD1zLkW5OlM4KM7:TR?=	MW\TRW5ITVJ?
A204	NWLCWINTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVfJR\|UxRTFwNUm4NFEh\|ryP	MmHEV2FPT0WU
NCI-H1304	NE\sb3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmfoTWM2OD1zLk[zOVkyKM7:TR?=	NFzsdnZUSU6JRWK=
Becker	M1rEVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUTJR\|UxRTFwNkSyOFEh\|ryP	NVGyc20xW0GQR1XS
OE19	NXK5RXBiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV3JR\|UxRTFwNkW1NVgh\|ryP	MXzTRW5ITVJ?
EKVX	M1:2OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHPYb\|lKSzVyPUGuOlU3OThizszN	MVXTRW5ITVJ?
KLE	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3zoSGlEPTB;MT62OVcyPCEQvF2=	MlXyV2FPT0WU
K-562	NHWyfVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3fuTmlEPTB;MT62O\|A{PyEQvF2=	M4\EOnNCVkeHUh?=
MDA-MB-175-VII	NGL0ZXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MliwTWM2OD1zLk[4PVk4KM7:TR?=	MnfrV2FPT0WU
NCI-H716	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M17vc2lEPTB;MT62PVMxPCEQvF2=	NWfY[FJwW0GQR1XS
Caov-3	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkHMTWM2OD1zLk[5OFE{KM7:TR?=	NV76fI1ZW0GQR1XS
HCC1187	Mn2yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2jyNmlEPTB;MT63NFU1PSEQvF2=	NIHlV\|dUSU6JRWK=
CAKI-1	NV74dXJmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn\hTWM2OD1zLkeyNlkzKM7:TR?=	NV6zOZZYW0GQR1XS
MOLT-16	MoP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NI\lXlNKSzVyPUGuO\|M{ODdizszN	Mn3mV2FPT0WU
PC-3	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmnITWM2OD1zLke1NFgh\|ryP	NWXReo5OW0GQR1XS
DV-90	NUXFNIdrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlfpTWM2OD1zLke1OVg2KM7:TR?=	NFjmbIdUSU6JRWK=
RXF393	NVzTboNET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHrEPW9KSzVyPUGuO\|czQTRizszN	NXnyNJRnW0GQR1XS
SK-NEP-1	NIfabWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV33NWs2UUN3ME2xMlgzOzN7IN88US=>	MnrnV2FPT0WU
HCC1419	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkS4TWM2OD1zLkiyOlkzKM7:TR?=	MV;TRW5ITVJ?
BV-173	MoXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlfKTWM2OD1zLkiyPVk2KM7:TR?=	Mn3mV2FPT0WU
MKN7	M1js[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4fhT2lEPTB;MT64PVIzKM7:TR?=	NVKxcYJVW0GQR1XS
LAN-6	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVHlZlJxUUN3ME2xMlg6PTV\|IN88US=>	NEH1UoxUSU6JRWK=
Mo-T	MmrGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3HoUmlEPTB;MT65NFA{QSEQvF2=	MkOyV2FPT0WU
HCC1395	Mm\HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkD4TWM2OD1zLkmyPFY{KM7:TR?=	NGfLblFUSU6JRWK=
HC-1	M3y1fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWraSG1rUUN3ME2xMlk{PDdizszN	MnTXV2FPT0WU
HPAF-II	M37xemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkToTWM2OD1zLkm0OFE5KM7:TR?=	MlLVV2FPT0WU
CPC-N	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWfJR\|UxRTFwOUiwNFIh\|ryP	NEPCTXNUSU6JRWK=
MKN45	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUjJR\|UxRTFwOUmxNVkh\|ryP	MUTTRW5ITVJ?
NCI-H1693	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX\temw2UUN3ME2yMlAxPDN\|IN88US=>	NFnGcIxUSU6JRWK=
SHP-77	NU\qWotIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWLJR\|UxRTJwMEC1N\|Mh\|ryP	MXrTRW5ITVJ?
NCI-H1522	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnuxTWM2OD1{LkCxO\|I1KM7:TR?=	M2j6UXNCVkeHUh?=
SW1573	NG\QeIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHfPVoxKSzVyPUKuNFIzKM7:TR?=	NHXtfoNUSU6JRWK=
DBTRG-05MG	Mn6zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWrJR\|UxRTJwME[wPFch\|ryP	NI\i[3RUSU6JRWK=
SCC-4	NVu1[49iT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWCwco1nUUN3ME2yMlE1OzFizszN	MojtV2FPT0WU
DMS-153	MlGxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXjZR5NOUUN3ME2yMlE3PjZ6IN88US=>	NXmzXohRW0GQR1XS
MDA-MB-415	NEf1VllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWLIVGV{UUN3ME2yMlE4PTJizszN	M2TFeXNCVkeHUh?=
NCI-H2126	NIr3bmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1vmW2lEPTB;Mj6yNlg5QCEQvF2=	Mk\pV2FPT0WU
MDA-MB-453	M3PqcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnXGTWM2OD1{LkKzN\|Ih\|ryP	NWG1Zog1W0GQR1XS
U-87-MG	NUfNeXlqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXPp[Zg{UUN3ME2yMlI5PTl{IN88US=>	MX7TRW5ITVJ?
LNCaP-Clone-FGC	NVjvS2FET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIW5OZZKSzVyPUKuN\|AyODJizszN	MoTLV2FPT0WU
NCI-H1581	MlriS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{e5WGlEPTB;Mj6zNlExPSEQvF2=	MXnTRW5ITVJ?
BC-3	NHjacmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3PBPWlEPTB;Mj6zOlUxQSEQvF2=	NXjRSno{W0GQR1XS
HCC38	M1vMeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MU\JR\|UxRTJwM{i0OFch\|ryP	M1PoVXNCVkeHUh?=
HCC2218	M2LzV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX[zUmd1UUN3ME2yMlQxQDB7IN88US=>	M4TM[nNCVkeHUh?=
RO82-W-1	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnLOTWM2OD1{LkSxNlUh\|ryP	NHPseWpUSU6JRWK=
C2BBe1	Mn75S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4rYeGlEPTB;Mj60NVU4QCEQvF2=	NV3KN2xUW0GQR1XS
LAMA-84	Mn;kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M12xOWlEPTB;Mj61O\|M3QCEQvF2=	MWjTRW5ITVJ?
GMS-10	NGTh[YVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkPYTWM2OD1{LkW3OlEyKM7:TR?=	NV7TfmdsW0GQR1XS
GCT	Ml7wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1u5TmlEPTB;Mj61PFY6PCEQvF2=	MWrTRW5ITVJ?
SK-CO-1	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHvJOWZKSzVyPUKuOlE3PiEQvF2=	MljJV2FPT0WU
NCI-H526	NUi2cm4xT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkKxTWM2OD1{Lk[zOFUh\|ryP	MorvV2FPT0WU
SW1088	MnXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHHReZpKSzVyPUKuO\|c5OzlizszN	MXHTRW5ITVJ?
HT55	Mmq4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2TNTmlEPTB;Mj63PFY6PSEQvF2=	MXLTRW5ITVJ?
NB10	MoS3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmjzTWM2OD1{LkixO\|Q5KM7:TR?=	MWLTRW5ITVJ?
UACC-893	M1nzfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2r3S2lEPTB;Mj64OVc1QSEQvF2=	MXPTRW5ITVJ?
NCI-H1618	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4HXZ2lEPTB;Mj64PFE2OyEQvF2=	MXnTRW5ITVJ?
NCI-H1092	NEnIWIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWHJR\|UxRTNwMEe4NVIh\|ryP	M3nZU3NCVkeHUh?=
SBC-1	M1n4bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGrVUWJKSzVyPUOuNFg2PTNizszN	MULTRW5ITVJ?
NCI-H1623	M2K4dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEPwO5FKSzVyPUOuNFk{PCEQvF2=	M2nMUHNCVkeHUh?=
SiHa	NUjIe4QxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlHGTWM2OD1\|LkGxPVc4KM7:TR?=	M2m2UnNCVkeHUh?=
D-263MG	MlGzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV;JR\|UxRTNwMUS3PFgh\|ryP	MVPTRW5ITVJ?
NCI-H1573	MorqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVvJR\|UxRTNwMUm2OFEh\|ryP	MUHTRW5ITVJ?
NCI-H82	MkLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3[yVmlEPTB;Mz6zOFQ{QSEQvF2=	MXPTRW5ITVJ?
NCI-H2196	M2\BPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUnxR5FiUUN3ME2zMlM2ODB6IN88US=>	M2PtPHNCVkeHUh?=
MFM-223	NWDye2dWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3f3eWlEPTB;Mz6zO\|M2OSEQvF2=	NHfzdGlUSU6JRWK=
COLO-678	NEXnZ\|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1LvcWlEPTB;Mz6zPFE5PiEQvF2=	NV:wUpRoW0GQR1XS
EW-3	M{jBd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NELTTZlKSzVyPUOuOFA6PSEQvF2=	MXjTRW5ITVJ?
MHH-NB-11	NXXOZnVOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIPh[W1KSzVyPUOuOFQxPjlizszN	NHu1Z4tUSU6JRWK=
EM-2	NEXjPJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVvwPYQ6UUN3ME2zMlY{QThizszN	NIfmTVRUSU6JRWK=
FTC-133	NILLPINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVXiXlBlUUN3ME2zMlY2PDV6IN88US=>	M1XFe3NCVkeHUh?=
NCI-H209	NV7idIR[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWjJZ2RHUUN3ME2zMlY4PjV\|IN88US=>	NX\udnc{W0GQR1XS
TGBC24TKB	Ml7HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHnxVFJKSzVyPUOuOlg{PTVizszN	M3TrWnNCVkeHUh?=
LC-1F	M4jS[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4P3ZWlEPTB;Mz63NVc3PCEQvF2=	MV;TRW5ITVJ?
C-4-II	MoW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3\NXGlEPTB;Mz63OVY1OyEQvF2=	NX\oWWNXW0GQR1XS
NCI-H1650	NIHVRo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEPvXJVKSzVyPUOuO\|g1PTVizszN	NHzOPXVUSU6JRWK=
JVM-2	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEK3OYZKSzVyPUOuPVM3OzlizszN	NV\NUJZLW0GQR1XS
CaR-1	MknPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYXJR\|UxRTNwOUe2NVch\|ryP	MX;TRW5ITVJ?
MDA-MB-134-VI	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGf0S2RKSzVyPUSuNFI6PTJizszN	M{XmTnNCVkeHUh?=
NCI-H719	NULle\|BET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXTJR\|UxRTRwMUWzPFgh\|ryP	MWrTRW5ITVJ?
GOTO	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUjJR\|UxRTRwMkm3NFUh\|ryP	NGDtPVdUSU6JRWK=
NCI-N87	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkLQTWM2OD12LkO4PFIyKM7:TR?=	MV3TRW5ITVJ?
NB6	NX7pXWw5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWHIc5NmUUN3ME20MlQzPTB7IN88US=>	NUjvNnFJW0GQR1XS
DSH1	NH\M[JhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHXwfHJKSzVyPUSuOFcyOTZizszN	M4mwTnNCVkeHUh?=
BT-20	M2nwTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF[2eFRKSzVyPUSuOFkxODJizszN	MoC2V2FPT0WU
NCI-H1882	NG\x[YhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnTjTWM2OD12LkWwOVch\|ryP	MXPTRW5ITVJ?
WM-115	NXfmOnRMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH\mb4RKSzVyPUSuOVA5QDFizszN	MV3TRW5ITVJ?
SKG-IIIa	M1vKdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NG\SRWlKSzVyPUSuOlc4PyEQvF2=	NIfyOHhUSU6JRWK=
NCI-H69	M3frcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnjpTWM2OD12LkewNlc2KM7:TR?=	M4TCPHNCVkeHUh?=
MSTO-211H	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIO0dXJKSzVyPUSuPFM2PjVizszN	MW\TRW5ITVJ?
Mewo	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVLJR\|UxRTRwOU[zNVMh\|ryP	MVPTRW5ITVJ?
GI-ME-N	M3O1d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnW2TWM2OD13LkCwOVA6KM7:TR?=	MUfTRW5ITVJ?
T98G	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHLwUFRKSzVyPUWuNFY2ODhizszN	Mof5V2FPT0WU
ECC4	Mle1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXHJR\|UxRTVwMEmzO\|Ih\|ryP	NEjB[HZUSU6JRWK=
EW-11	NWWx[WdoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2fVO2lEPTB;NT6xPFA6QSEQvF2=	Ml\3V2FPT0WU
COLO-800	Ml\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NY[xSWoxUUN3ME21MlE6OzR7IN88US=>	NVzUO5J3W0GQR1XS
NCI-H1755	M3XhUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV33fpp6UUN3ME21MlI{ODJ5IN88US=>	NY\Xd2w6W0GQR1XS
KMS-12-PE	M2rCbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1rnWWlEPTB;NT6zOVA5PSEQvF2=	MkHvV2FPT0WU
HCC1954	MnPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2LUVWlEPTB;NT64OVk4OSEQvF2=	NWe5SWxnW0GQR1XS
NCI-H187	MknjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUnJR\|UxRTVwOUK5PFkh\|ryP	NFXLb45USU6JRWK=
LU-165	M3zWfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mmq0TWM2OD13Lkm5NFAzKM7:TR?=	NFz4c2dUSU6JRWK=
YAPC	Mo\WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{HoXWlEPTB;NT65PVA3QCEQvF2=	MWnTRW5ITVJ?
LU-139	NFm3Z3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M37VVGlEPTB;Nj6wPFM3QCEQvF2=	NXHxfIdpW0GQR1XS
D-502MG	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWXJR\|UxRTZwM{KwOFch\|ryP	M2jmcHNCVkeHUh?=
IST-SL1	NUTwXXNuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoTQTWM2OD14LkWzPVQ5KM7:TR?=	NGLIVHpUSU6JRWK=
DG-75	NELjZYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYnnN4kzUUN3ME22Mlg5Pzh4IN88US=>	NFvaS4lUSU6JRWK=
NCI-H1155	NGiy[5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVfJR\|UxRTZwOUW1PFEh\|ryP	MmXvV2FPT0WU
EFE-184	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIXYdolKSzVyPUeuN\|E3QTVizszN	NHfKWoJUSU6JRWK=
AsPC-1	NEPhT\|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MljqTWM2OD15LkS4PFA4KM7:TR?=	MlPOV2FPT0WU
SW948	MlroS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWDJR\|UxRTdwNUizPVUh\|ryP	MoTkV2FPT0WU
NCI-H524	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFnpbFdKSzVyPUmuOVg3OjhizszN	NHvmb3hUSU6JRWK=
KOSC-2	NHnzUpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV\JR\|UxRTlwNkK4N\|Qh\|ryP	Ml3lV2FPT0WU
T-24	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUnJR\|UxRTlwOUS0NVUh\|ryP	NVvZ[mQ{W0GQR1XS
NCI-H748	M4PaPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{TmVmlEPTB;MUCuOlM6PyEQvF2=	NXHD[IJHW0GQR1XS
NCI-H23	NYjZfpR5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF\nWmlKSzVyPUGwMlY1PDJizszN	NW\OVI9YW0GQR1XS
UACC-812	NX7LPXh4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NID3PVJKSzVyPUGxMlcyPyEQvF2=	M{jIeHNCVkeHUh?=
SCLC-21H	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVLmNG9bUUN3ME2xNk4yPTVzIN88US=>	NELubGNUSU6JRWK=
NCI-SNU-16	MlK2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWDJR\|UxRTF\|LkGyOVgh\|ryP	M4jHS3NCVkeHUh?=
HD-MY-Z	MnjVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF;TfnJKSzVyPUG0MlY{PjNizszN	Mn7nV2FPT0WU
SK-N-FI	NG\GNmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFjV[mhKSzVyPUG0Mlg6OTJizszN	NEDaUpZUSU6JRWK=
LB647-SCLC	M3XXdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mo[xTWM2OD1zNT63NVk2KM7:TR?=	M2fzWHNCVkeHUh?=
NCI-H345	M2XETmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYfJR\|UxRTF5LkO0N{DPxE1?	M1PkcXNCVkeHUh?=
NCI-H1563	NXjrWWpTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUWwcWlPUUN3ME2xPE44PjBzIN88US=>	NH7OS21USU6JRWK=
RL	NITEU5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXrJR\|UxRTJzLkK2OVYh\|ryP	MXvTRW5ITVJ?
KY821	MkGyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2\nUGlEPTB;MkKuNFU2OyEQvF2=	NUC1XXpZW0GQR1XS
JVM-3	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml\kTWM2OD1{NT6wOFE{KM7:TR?=	NH;YeIFUSU6JRWK=
NCI-H1793	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEXTfWdKSzVyPUK4MlU1QTlizszN	MUXTRW5ITVJ?
LU-134-A	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4HZSmlEPTB;M{CuNlA{PyEQvF2=	NWXp[\|lCW0GQR1XS
NCI-H1395	NYX4RpRtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX7vVHhRUUN3ME2zNk4zPDNzIN88US=>	MXXTRW5ITVJ?
NCI-H1993	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3;qc2lEPTB;M{KuPFIyQCEQvF2=	NYrjdFJyW0GQR1XS
P31-FUJ	Mo[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MofFTWM2OD1\|Mz60PFk6KM7:TR?=	NEXKRmtUSU6JRWK=
LS-513	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEnDR3VKSzVyPUO1Mlg5PzlizszN	MnuxV2FPT0WU
SK-MEL-1	M{LnZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M360OWlEPTB;NECuN\|Q6QSEQvF2=	MknvV2FPT0WU
SW684	MmjQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWfJR\|UxRTR\|Lkm2OlEh\|ryP	MonYV2FPT0WU
COR-L88	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXPnclMyUUN3ME20OE4xPjZ3IN88US=>	NV\YPYYyW0GQR1XS
NCI-H889	M3zidWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlLtTWM2OD12NT6wNFg4KM7:TR?=	MkfuV2FPT0WU
TALL-1	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXjYSWdsUUN3ME20Ok4yOTl7IN88US=>	MV;TRW5ITVJ?
KARPAS-299	NWPGRXN2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mmf0TWM2OD12Nz6xPVk{KM7:TR?=	NY\QOZFiW0GQR1XS

... Click to View More Cell Line Experimental Data

In vivo

Obatoclax also exhibits high antitumor activity in SCID mice bearing human C33A cerivical carcinoma tumors at a dose of 0.5 mg/kg. ^[1]

Protocol

Kinase Assay:^[1]	+ Expand Bcl-2 Binding affinity calculation: A predicted binding affinity for Obatoclax binding to BCL-2 is calculated using the SIE scoring function. ^[4] As a control in determining the reliability of the calculation, predicted binding affinities K_i) are calculated for a set of 12 small molecules with experimentally measured binding affinities to BCL-2.
Cell Research:^[2]	+ Expand Cell lines: Human MM cells (HMCLs), peripheral blood lymphocytes (PBLs), bone marrow stromal cells (BMSCs) Concentrations: ~10 μM Incubation Time: 48-72 hours Method: Obatoclax is dissolved in DMSO at a stock concentration of 5 mM. Cell viability is assayed by MTT. Human MM cells (HMCLs), peripheral blood lymphocytes (PBLs), bone marrow stromal cells (BMSCs) are seeded in 96-well plates at a density of 2 × 10⁴ per well for HMCLs or 5~10 × 10³ for PBLs. Various concentrations of Obatoclax are added to the cells, with or without IGF-1 (50 ng/mL) or IL-6 (10 ng/mL). Cells are incubated for 48-72 hours and cell viability is determined. (Only for Reference)
Animal Research:^[1]	+ Expand Animal Models: Female BALB/c or CB17 SCID/SCID mice bearing SW480, C33A, PC3, and 4T1 cells are used. Formulation: Obatoclax (tartrate salt) is formulated in 9.6% polyethylene glycol 300, 0.4% polysorbate 20, and 5% dextrose; while for the 4T1 tumor model, Obatoclax is formulated at a concentration of 0.6 mg/mL in 9.48% polyethylene glycol, 0.38% polysorbate 20, 1.2 m Dosages: 0.0313, 0.25, 0.5 and 2 mg/kg Administration: Administered intravenously (tail vein) once a day (Only for Reference)

References

[4] Naim M, et al. J Chem Inf Model, 2007, 47(1), 122-133.

+ Expand

Solubility (25°C)

In vitro	DMSO	83 mg/mL (200.73 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 30% PEG400+0.5% Tween80+5% propylene glycol For best results, use promptly after mixing.	30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Obatoclax Mesylate (GX15-070) SDF

Molecular Weight	413.49
Formula	C₂₀H₁₉N₃O.CH₄O₃S
CAS No.	803712-79-0
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2018-10-19)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT01563601	Withdrawn	Extensive-stage Small Cell Lung Cancer	Cephalon\|Teva Pharmaceutical Industries	August 2012	Phase 3
NCT01238146	Withdrawn	Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue\|Nodal Marginal Zone B-cell Lymphoma\|Recurrent Grade 1 Follicular Lymphoma\|Recurrent Grade 2 Follicular Lymphoma\|Recurrent Mantle Cell Lymphoma\|Recurrent Marginal Zone Lymphoma\|Splenic Marginal Zone Lymphoma	National Cancer Institute (NCI)	October 2010	Phase 1\|Phase 2
NCT01150656	Completed	Leukemia	Children''s Oncology Group\|National Cancer Institute (NCI)	June 2010	--
NCT00933985	Terminated	Acute Leukemias of Ambiguous Lineage\|Acute Undifferentiated Leukemia\|Angioimmunoblastic T-cell Lymphoma\|Blastic Phase Chronic Myelogenous Leukemia\|Childhood Burkitt Lymphoma\|Childhood Chronic Myelogenous Leukemia\|Childhood Diffuse Large Cell Lymphoma\|Childhood Immunoblastic Large Cell Lymphoma\|Childhood Nasal Type Extranodal NK/T-cell Lymphoma\|Cutaneous B-cell Non-Hodgkin Lymphoma\|Hepatosplenic T-cell Lymphoma\|Intraocular Lymphoma\|Noncutaneous Extranodal Lymphoma\|Peripheral T-cell Lymphoma\|Recurrent Childhood Acute Lymphoblastic Leukemia\|Recurrent Childhood Acute Myeloid Leukemia\|Recurrent Childhood Anaplastic Large Cell Lymphoma\|Recurrent Childhood Grade III Lymphomatoid Granulomatosis\|Recurrent Childhood Large Cell Lymphoma\|Recurrent Childhood Lymphoblastic Lymphoma\|Recurrent Childhood Small Noncleaved Cell Lymphoma\|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma\|Recurrent Mycosis Fungoides/Sezary Syndrome\|Recurrent/Refractory Childhood Hodgkin Lymphoma\|Refractory Chronic Lymphocytic Leukemia\|Refractory Hairy Cell Leukemia\|Relapsing Chronic Myelogenous Leukemia\|Small Intestine Lymphoma\|Unspecified Childhood Solid Tumor Protocol Specific	National Cancer Institute (NCI)	June 2009	Phase 1
NCT00521144	Completed	Recurrent Small Cell Lung Cancer\|Unspecified Adult Solid Tumor Protocol Specific	National Cancer Institute (NCI)	August 2007	Phase 1\|Phase 2
NCT00427856	Completed	Lymphoma Follicular	Gemin X\|Teva Pharmaceutical Industries	March 2007	Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Pan Bcl-2 Inhibitor

ABT-737 : Bcl-xL, EC50=78.7 nM; Bcl-2, EC50=30.3 nM; Bcl-w, EC50=197.8 nM.
Most Potent Bcl-2 Inhibitor

ABT-263 (Navitoclax) : Bcl-xL, K_i≤ 0.5 nM; Bcl-2, K_i≤ 1 nM; Bcl-w, K_i≤ 1 nM.
Newest Bcl-2 Family Activator

BAM7 : Direct and selective activator of proapoptotic Bax with EC50 of 3.3 μM.
Classic Bcl-2 Inhibitor

ABT-737 : BH3-mimetic inhibitor, Bcl-xL, EC50=78.7 nM; Bcl-2, EC50=30.3 nM; Bcl-w, EC50=197.8 nM.

Related Bcl-2 Products

A-1210477 ^New

A-1210477 is a potent and selective MCL-1 inhibitor with K_i and IC50 of 0.454 nM and 26.2 nM, respectively, >100-fold selectivity over other Bcl-2 family members.
MI-773 (SAR405838) ^New

MI-773 (SAR405838) is an orally available MDM2 antagonist with K_i of 0.88 nM. Phase 1.
Navitoclax (ABT-263)

Navitoclax (ABT-263) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with K_i of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.
Venetoclax (ABT-199, GDC-0199)

Venetoclax (ABT-199, GDC-0199) is a Bcl-2-selective inhibitor with K_i of <0.01 nM in cell-free assays, >4800-fold more selective versus Bcl-xL and Bcl-w, and no activity to Mcl-1. Phase 3.

Features:Re-engineered version of ABT-263 (Navitoclax).
ABT-737

ABT-737 is a BH3 mimetic inhibitor of Bcl-xL, Bcl-2 and Bcl-w with EC50 of 78.7 nM, 30.3 nM and 197.8 nM in cell-free assays, respectively; no inhibition observed against Mcl-1, Bcl-B or Bfl-1. Phase 2.
UMI-77

UMI-77 is a selective Mcl-1 inhibitor with Ki of 490 nM, showing selectivity over other members of Bcl-2 family.
TW-37

TW-37 is a novel nonpeptide inhibitor to recombinant Bcl-2, Bcl-xL and Mcl-1 with K_i of 0.29 μM, 1.11 μM and 0.26 μM in cell-free assays, respectively.
Sabutoclax

Sabutoclax(BI-97C1) is a pan-Bcl-2 inhibitor, including Bcl-xL, Bcl-2, Mcl-1 and Bfl-1 with IC50 of 0.31 μM, 0.32 μM, 0.20 μM and 0.62 μM, respectively.
AT101

AT101, the R-(-) enantiomer of Gossypol acetic acid, binds with Bcl-2, Bcl-xL and Mcl-1 with K_i of 0.32 μM, 0.48 μM and 0.18 μM in cell-free assays; does not inhibit BIR3 domain and BID. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Obatoclax Mesylate (GX15-070)

Cited by 26 Publications

9 Customer Reviews

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Obatoclax Mesylate (GX15-070) SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2018-10-19)

Tech Support

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Related Bcl-2 Products

Choose Your Country or Region

By Signaling Pathways

By product type

Obatoclax Mesylate (GX15-070)

Cited by 26 Publications

9 Customer Reviews

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Obatoclax Mesylate (GX15-070) SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2018-10-19)

Tech Support

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Related Bcl-2 Products

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)